



INVESTMENTS

806.7

EUR MILLION
(+2.5%)

CONSOLIDATED FINANCIAL STATEMENTS

78
CONSOLIDATED STATEMENT
OF INCOME

78
CONSOLIDATED STATEMENT
OF COMPREHENSIVE INCOME

79
CONSOLIDATED STATEMENT
OF FINANCIAL POSITION

80
CONSOLIDATED ASSET ANALYSIS

82
CONSOLIDATED STATEMENT
OF CHANGES IN EQUITY

84
CONSOLIDATED STATEMENT
OF CASH FLOWS

85
NOTES

153
INDEPENDENT AUDITORS' REPORT

154
MAJOR SHAREHOLDINGS

CONSOLIDATED STATEMENT OF INCOME

	Notes	2016 € '000	2015 € '000
Sales	1)	6,470,978	6,129,770
Cost of goods sold	2)	- 3,608,096	- 3,447,085
Gross profit		2,862,882	2,682,685
Selling expenses	3)	- 1,635,202	- 1,579,030
General and administrative expenses		- 323,989	- 308,890
Research and development expenses	4)	- 291,416	- 262,395
Interim profit		612,275	532,370
Other operating income	5)	299,783	410,899
Other operating expenses	6)	- 329,886	- 460,409
Operating profit		582,172	482,860
Profit from financial investments/equity method	7)	17,724	18,913
Financial income		6,436	5,198
Financial expenses		- 76,050	- 76,625
Net financial income (loss)	8)	- 69,614	- 71,427
Other financial income (loss)	9)	- 2,509	15,173
Profit before taxes		527,773	445,519
Income taxes	10)	- 131,771	- 125,802
Consolidated net income		396,002	319,717
Attributable to:			
B. Braun Melsungen AG Shareholders		(373,321)	(305,410)
Non-controlling interests		(22,681)	(14,307)
		396,002	319,717
Earnings per share (in €) for B. Braun Melsungen AG shareholders in the fiscal year (diluted and undiluted)	11)	19,24	15,74

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	2016 € '000	2015 € '000
Consolidated net income	396,002	319,717
Items not reclassified as profits or losses		
Revaluation of pension obligations	- 184,460	71,500
Income taxes	51,840	- 18,555
Changes in amount recognized in equity	- 132,620	52,945
Items potentially reclassified as profits or losses		
Changes in fair value of securities	165	- 258
Income taxes	0	0
Changes in amount recognized in equity	165	- 258
Changes in fair value of financial derivatives	- 6,638	- 138
Income taxes	2,113	120
Changes in amount recognized in equity	- 4,525	- 18
Changes due to currency translation	67,386	10,481
Income taxes	0	0
Changes in amount recognized in equity	67,386	10,481
Changes recognized directly in equity (after taxes)	- 69,594	63,150
Comprehensive income in the reporting year	326,408	382,867
Attributable to:		
B. Braun Melsungen AG shareholders	(302,248)	(357,353)
Non-controlling interests	(24,160)	(25,514)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Notes	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Assets			
Non-current assets			
Intangible assets	14) 16)	623,335	566,648
Property, plant, and equipment	15) 16)	3,987,336	3,642,325
Financial investments (equity method)	17)	389,369	338,942
Other financial investments	17)	50,305	45,984
of which financial assets		(50,305)	(45,984)
Trade receivables	18)	27,534	20,186
Other assets	19)	45,289	28,144
of which financial assets		(40,990)	(23,853)
Income tax receivables		1,412	1,873
Deferred tax assets		288,616	203,439
		5,413,196	4,847,541
Current assets			
Inventories	20)	1,135,378	1,056,725
Trade receivables	18)	1,061,545	1,014,515
Other assets	19)	235,204	238,300
of which financial assets		(99,599)	(126,733)
Income tax receivables		46,029	46,093
Cash and cash equivalents	21)	90,456	62,958
		2,568,612	2,418,591
Total assets		7,981,808	7,266,132
Equity			
Subscribed capital	22)	800,000	800,000
Capital reserves and retained earnings	23)	2,187,570	1,996,404
Effects of foreign currency translation		- 21,667	- 86,408
Equity attributable to B. Braun Melsungen AG shareholders		2,965,903	2,709,996
Non-controlling interests	24)	206,049	190,380
Total equity		3,171,952	2,900,376
Liabilities			
Non-current liabilities			
Provisions for pensions and similar obligations	25)	1,300,833	1,079,705
Other provisions	26)	112,694	98,235
Financial liabilities	27)	1,186,183	1,154,991
Trade accounts payable	29)	4,639	4,502
Other liabilities	29)	37,795	39,842
of which financial liabilities		(11,346)	(19,251)
Deferred tax liabilities		108,702	99,740
		2,750,846	2,477,015
Current liabilities			
Other provisions	26)	48,670	49,632
Financial liabilities	27)	805,945	768,374
Trade accounts payable	29)	438,240	344,113
Other liabilities	29)	716,917	681,183
of which financial liabilities		(309,985)	(286,486)
Current income tax liabilities		49,238	45,439
		2,059,010	1,888,741
Total liabilities		4,809,856	4,365,756
Total equity and liabilities		7,981,808	7,266,132

CONSOLIDATED ASSET ANALYSIS

Group	Costs of acquisition and manufacture					
	Jan. 1, 2016	Foreign currency translation	Additions to scope of consolidation	Disposals from scope of consolidation	Additions	Transfers
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
Intangible assets						
Acquired goodwill	183,629	1,794	19,179	206	0	0
Licenses, trademarks, and other similar rights	473,620	6,650	8,961	- 157	30,192	32,048
Internally created intangible assets	108,400	3,369	0	0	10,097	0
Advance payments	111,912	36	0	0	24,627	- 30,104
Total	877,561	11,849	28,140	49	64,916	1,944
Property, plant, and equipment						
Land and buildings	1,978,173	22,774	215	0	52,380	100,058
Technical plants and machinery	2,911,868	33,206	162	0	70,222	225,134
Other plants, operating and office equipment	937,932	22,527	1,198	0	78,100	33,422
Advance payments and assets under construction	619,974	5,509	0	0	445,214	- 360,558
Total	6,447,947	84,016	1,575	0	645,916	- 1,944
Financial investments						
Financial investments (equity method)	338,942	- 3	0	0	50,430	0
Other holdings	30,497	0	0	- 7,744	15,319	0
Loans to companies in which the Group holds an interest	402	70	0	0	0	0
Securities	5,185	0	0	0	0	0
Other loans	9,949	1	0	0	671	0
Total	384,975	68	0	- 7,744	66,420	0
	7,710,483	95,933	29,715	- 7,695	777,252	0

* Other changes include foreign currency translation effects, changes to the consolidation scope, transfers and disposals.

	Disposals	Changes in fair value	Dec. 31, 2016	Depreciation and amortization				Carrying amounts				
				€ '000	€ '000	€ '000	Accu- mulated 2015	Fiscal year 2016	Other changes*	Accu- mulated 2016	Dec. 31, 2016	Dec. 31, 2015
							€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
	0	0	204,808	503	0	0	503	204,305	183,126			
	-6,574	0	544,740	294,420	38,131	2,937	335,488	209,252	179,200			
	0	0	121,866	15,990	1,571	583	18,144	103,722	92,410			
	-415	0	106,056	0	0	0	0	106,056	111,912			
	-6,989	0	977,470	310,913	39,702	3,520	354,135	623,335	566,648			
	-4,508	0	2,149,092	552,198	61,416	1,632	615,246	1,533,846	1,425,975			
	-45,230	0	3,195,362	1,639,494	191,363	-24,115	1,806,742	1,388,620	1,272,374			
	-33,104	0	1,040,075	610,636	81,323	-11,795	680,164	359,911	327,296			
	-694	0	709,445	3,294	3,849	-2,657	4,486	704,959	616,680			
	-83,536	0	7,093,974	2,805,622	337,951	-36,935	3,106,638	3,987,336	3,642,325			
	0	0	389,369	0	0	0	0	389,369	338,942			
	-1,336	0	36,736	29	0	0	29	36,707	30,468			
	-80	0	392	0	0	0	0	392	402			
	0	188	5,373	0	2,519	0	2,519	2,854	5,185			
	-249	0	10,372	20	0	0	20	10,352	9,929			
	-1,665	188	442,242	49	2,519	0	2,568	439,674	384,926			
	-92,190	188	8,513,686	3,116,584	380,172	-33,415	3,463,341	5,050,345	4,593,899			

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

See notes 22–24	Subscribed capital	Capital reserves
	€ '000	€ '000
January 1, 2015	800,000	10,226
Dividend of B. Braun Melsungen AG	0	0
Increase in subscribed capital	0	0
Consolidated net income	0	0
Changes recognized directly in equity (after taxes)		
Changes in fair value of securities	0	0
Cash flow hedging instruments	0	0
Revaluation of pension obligations	0	0
Changes due to currency translation	0	0
Comprehensive income over the period	0	0
Other changes	0	0
December 31, 2015/January 1, 2016	800,000	10,226
Dividend of B. Braun Melsungen AG	0	0
Increase in subscribed capital	0	0
Consolidated net income	0	0
Changes recognized directly in equity (after taxes)		
Changes in fair value of securities	0	0
Cash flow hedging instruments	0	0
Revaluation of pension obligations	0	0
Changes due to currency translation	0	0
Comprehensive income over the period	0	0
Other changes	0	0
December 31, 2016	800,000	10,226

	Retained earnings	Other reserves	Equity attributable to owners	Non-controlling interests	Equity
	€ '000	€ '000	€ '000	€ '000	€ '000
	1,660,984	- 87,629	2,383,581	180,436	2,564,017
	- 32,000	0	- 32,000	0	- 32,000
	0	0	0	0	0
	305,410	0	305,410	14,307	319,717
	0	- 254	- 254	- 4	- 258
	0	- 140	- 140	122	- 18
	0	0	54,797	- 1,852	52,945
	54,797	- 2,460	- 2,460	12,941	10,481
	0	- 2,854	357,353	25,514	382,867
	1,062	0	1,062	- 15,570	- 14,508
	1,990,253	- 90,483	2,709,996	190,380	2,900,376
	- 32,000	0	- 32,000	0	- 32,000
	0	0	0	0	0
	373,321	0	373,321	22,681	396,002
	0	155	155	10	165
	0	- 4,237	- 4,237	- 288	- 4,525
	- 131,731	0	- 131,731	- 889	- 132,620
	0	64,740	64,740	2,646	67,386
	241,590	60,658	302,248	24,160	326,408
	- 14,341	0	- 14,341	- 8,491	- 22,832
	2,185,502	- 29,825	2,965,903	206,049	3,171,952

CONSOLIDATED STATEMENT OF CASH FLOWS

	Notes	2016 € '000	2015 € '000
Operating profit		582,172	482,860
Income tax paid		- 145,883	- 124,171
Depreciation and amortization of property, plant, and equipment and intangible assets (net of appreciation)		377,653	361,127
Change in non-current provisions		232,131	- 6,338
Interest received and other financial income		5,215	855
Interest paid and other financial expenditure		- 43,540	- 47,624
Other non-cash income and expenses		- 259,230	94,760
Gain/loss on the disposal of property, plant, and equipment and intangible or other assets		4,691	6,223
Gross cash flow	34)	753,209	767,692
Change in inventories		- 57,988	- 34,823
Change in receivables and other assets		- 16,782	- 78,820
Change in liabilities, current provisions and other liabilities (excluding financial liabilities)		144,340	33,456
Cash flow from operating activities (net cash flow)	34)	822,779	687,505
Investments in property, plant, and equipment and intangible assets		- 739,826	- 695,580
Investments in financial assets		- 42,898	- 22,809
Acquisitions of subsidiaries, net of cash acquired		- 20,705	- 39,049
Proceeds from sale of subsidiaries and holdings		3,265	4,034
Proceeds from sale of property, plant, and equipment, intangible assets and other financial assets		3,804	11,151
Dividends and similar revenues received		13,277	29,355
Cash flow from investing activities	35)	- 783,083	- 712,898
Free cash flow		39,696	- 25,393
Capital contributions		2,271	237
Dividends paid to B. Braun Melsungen AG shareholders		- 32,000	- 32,000
Dividends paid to non-controlling interests		- 9,451	- 10,052
Deposits and repayments for profit-sharing rights		- 88	- 1,154
Loans		340,316	340,888
Loan repayments		- 290,929	- 304,223
Cash flow from financing activities	36)	10,119	- 6,304
Change in cash and cash equivalents		49,815	- 31,697
Cash and cash equivalents at the start of the year		62,958	84,332
Exchange gains (losses) on cash and cash equivalents		- 22,317	10,323
Cash and cash equivalents at year end	37)	90,456	62,958

NOTES

GENERAL INFORMATION

The consolidated financial statements of B. Braun Melsungen AG – hereinafter also referred to as the B. Braun Group – as of December 31, 2016, have been prepared in compliance with Section 315a (3) of the German Commercial Code (HGB) according to International Financial Reporting Standards (IFRS) applicable as of the reporting date published by the International Accounting Standards Board (IASB), London, as well as the interpretations issued by the International Financial Reporting Interpretations Committee (IFRIC) as stipulated by the EU, and have been published in the online edition of the German Federal Gazette (Bundesanzeiger).

B. Braun Melsungen AG is a globally engaged, family-owned company headquartered in Melsungen, Germany. The company's address is Carl-Braun-Str. 1, 34212 Melsungen. B. Braun Melsungen AG is registered in the commercial registry of the Fritzlar Administrative Court (HR B 11000).

B. Braun Holding GmbH & Co. KG in Melsungen is the parent company of B. Braun Melsungen AG, as defined in Section 290 (1) HGB, and as the chief parent company is required to produce consolidated financial statements that include the consolidated financial statements of B. Braun Melsungen AG. The consolidated financial statements are submitted to the online edition of the German Federal Gazette (Bundesanzeiger).

B. Braun Melsungen AG and its subsidiaries manufacture, market and sell a broad array of health care products and services for intensive care units, anesthesia and emergency care, extracorporeal blood treatment, and surgical core procedures. The major manufacturing facilities are located in the EU, Switzerland, the USA, Brazil, Vietnam and Malaysia. The company distributes its products via a worldwide network of subsidiaries and associated companies.

The Management Board of B. Braun Melsungen AG approved the consolidated financial statements for submission to the company's Supervisory Board on March 8, 2017. The Audit Committee of the Supervisory Board plans to discuss the consolidated financial statements at its meeting on March 20, 2017, and the Supervisory Board shall approve the consolidated financial statements at its meeting on March 28, 2017.

The consolidated financial statements have been prepared based on historical costs, except for available-for-sale financial assets and financial assets/liabilities including derivative financial instruments measured at fair value through profit and loss. Unless otherwise indicated, the accounting policies were used consistently for all periods referred to in this report.

In the statement of financial position, a distinction is made between current and non-current assets and liabilities. The statement of income is presented using the cost-of-goods-sold method. Using this format, net sales are compared to expenses incurred to generate these sales, classified by the expense categories cost of goods sold, selling, general and administrative, and research and development. To improve the informational content of the consolidated statement of financial position and consolidated statement

of income, further details on individual entries have been provided in the notes to the consolidated financial statements. The consolidated financial statements have been prepared in euros. Unless otherwise stated, all figures are presented in thousands of euros (€ '000).

The financial statements of B. Braun Melsungen AG and its subsidiaries included in the consolidated financial statements have been prepared using standardized Group accounting policies.

New and amended International Financial Reporting Standards and Interpretations whose application is mandatory for the first time for fiscal years beginning on or after February 1, 2015 (IAS 8.28)

Amendments to IAS 19 Employee Benefits – Employee Contributions

The amendment to IAS 19R (2011) adds an option to the standard with regard to accounting for defined benefit pension plans in which employees (or third parties) are involved through mandatory contributions. IAS 19R (2011) provides for assigning employee contributions, which are set out in the formal terms of a defined benefit plan and linked to job performance, to the service periods as negative benefits. Taking into account the now-published amendment to IAS 19R (2011), it is permissible to continue recognizing employee contributions linked to job performance that are not linked to the number of years of service during that period in which the corresponding work is done without applying the calculation-and-distribution method, using the "projected unit credit method." However, if the employee contributions – depending on the number of years of service – vary, it is mandatory that the calculation-and-distribution method using the "projected unit credit method" be followed. This amendment should be applied for fiscal years beginning on or after February 1, 2015. The B. Braun Group did not opt to apply the amendment earlier. The amendment is expected to have no material impact on the net assets, financial position and earnings situation of the B. Braun Group.

New and amended International Financial Reporting Standards and Interpretations whose application is mandatory for the first time for fiscal years beginning on or after January 1, 2016 (IAS 8.28)

Amendments to IFRS 11 Joint Arrangements – Acquisition of Shares in a Joint Operation

The amendment clarifies that acquisitions and subsequent acquisitions of interests in jointly controlled operations, which constitute a business as defined by IFRS 3, Business Combinations, should be accounted for according to the principles of accounting for business combinations under IFRS 3 and other applicable IFRS, provided these do not conflict with the provisions in IFRS 11. The changes do not apply if the reporting entity and the parties thereto are under common control of the same ultimate controlling party. The new rules apply prospectively for share purchases that take place in reporting periods beginning on or after January 1, 2016. The amendment is expected to have no material impact on the net assets, financial position and earnings situation of the B. Braun Group.

Amendments to IAS 16 Property, Plant, and Equipment, and IAS 38, Intangible Assets – Clarification of Acceptable Methods of Depreciation and Amortization

The aim of these amendments is to clarify which methods are appropriate with regard to the depreciation of property, plant and equipment and intangible assets. In principle, the depreciation of property, plant and equipment and intangible assets shall reflect the company's expected consumption of future

economic benefits generated by the asset. In this regard, the IASB has now clarified that a depreciation of property, plant, and equipment on the basis of the sales of goods that it manufactures does not follow this approach, and thus is not appropriate, because the revenues depend not only on consumption of the asset, but also on other factors, such as sales volume, price or inflation. With some exceptions, this clarification is also included in IAS 38 for amortizing intangible assets with finite useful lives. For both property, plant and equipment and intangible assets, the clarification also states that the decline in the sale prices of goods and services produced with them might be an indication of their economic obsolescence, and therefore an indication of a decline in the economic benefit potential of the assets that are necessary for production. This amendment applies to reporting periods beginning on or after January 1, 2016. It is expected to have no material impact on the net assets, financial position and earnings situation of the B. Braun Group.

Amendments to IAS 1 Presentation of Financial Statements: Disclosure Initiative

The objective of the information initiative is to eliminate obstacles that authors are faced with while exercising discretion when presenting financial statements. With respect to materiality, the amendments clarify that information should not be obscured by aggregating, that materiality must be applied to all elements of financial statements, and that, even then, significance shall be taken into account when the disclosure of certain information is prescribed in a standard. With regard to the statement of financial position and the representation in the income statement or in other comprehensive income, it is clarified that the list of ID lines can be split up or combined in the components of the financial statement on grounds of relevance and that additional guidance regarding subtotals in the financial statement components apply. It is clarified that a company's share of the other comprehensive income of associates or joint ventures that is accounted for using the equity method and aggregated as single ID lines on the basis of whether they are later recycled in the income statement should be identified. In terms of information, additional examples of possible sequences of information are included to clarify that understandability and comparability should be considered when the order of the information is being determined, and that the information does not have to be given in the order that is currently shown in IAS 1.114. In addition, those rules and examples referring to naming the significant accounting and valuation methods were eliminated if they were perceived as potentially unhelpful. These amendments are effective for fiscal years beginning on or after January 1, 2016. As the amendment merely affects the presentation of the financial statement, it will have no impact on the net assets, financial position and earnings situation of the B. Braun Group.

Amendments to IFRS 10, Consolidated Financial Statements, and IAS 28, Investments in Associate Corporations and Joint Ventures

The amendments have resolved a previously existing inconsistency between the two standards. IFRS 10 currently requires recognizing the full profit or loss resulting from the loss of control of a subsidiary which is introduced in a joint venture or an associate concern. In contrast, IAS 28 only provides for profit or loss realization in the amount of shares held by other investors for non-financial assets introduced in associated companies or joint ventures. According to the published changes, in the future, the investor always has to realize a profit or loss in full if the transaction involves a business as defined in IFRS 3. If the transaction involves assets that do not constitute a business, then only the pro rata success shall be recognized. The changes should be applied prospectively to corresponding transactions beginning on

or after January 1, 2016. However, the IASB published a draft standard in August 2015 which calls for postponing mandatory first-time application indefinitely. This action was taken because of the finding of an unintended conflict between the proposed new rule and the existing rule in IAS 28.32. Nevertheless, voluntary earlier application of the rules will continue to be allowed. However, the amendment is not yet applicable because there has been no endorsement made for IFRS EU accounting. The rule is expected to have no material impact on the net assets, financial position and earnings situation of the B. Braun Group.

New and amended International Financial Reporting Standards and Interpretations that have already been published, but whose application is not yet mandatory for companies whose fiscal year ends on December 31, 2016 (IAS 8.30), and whose adoption is still pending in some EU countries

Amendments to IAS 12, Income Taxes

The IASB has published final amendments to IAS 12, Income Taxes, in order to address the diversity in practice around the recognition of a deferred tax asset that is related to an asset measured at fair value, which is mainly attributable to uncertainty about the application of some of the principles in IAS 12. The amendments clarify that unrealized losses on debt instruments measured at fair value and measured at cost for tax purposes result in a deductible temporary difference regardless of whether the debt instrument's holder expects to recover the carrying amount by holding the debt instrument until maturity or by selling it. They clarify that the carrying amount of an asset does not limit the estimation of probable future taxable profits and that estimates for future taxable profits exclude tax deductions resulting from the reversal of deductible temporary differences. They also clarify that a business must assess a deferred tax asset in combination with other deferred tax assets. Where tax law restricts the realization of tax losses, a business would assess a deferred tax asset in combination with other deferred tax assets of the same type. These amendments are effective for reporting periods beginning on or after January 1, 2017. Early application is permitted. Widespread EU adoption (endorsement) of these amendments is expected for Q2 2017. The amendments are expected to have no material impact on the net assets, financial position and earnings situation of the B. Braun Group.

Disclosure Initiative (Amendments to IAS 7, Consolidated Statement of Cash Flows)

The final amendments in the Disclosure Initiative (Amendments to IAS 7) pursue the IASB's objective that a company must provide disclosures that allow users of financial statements to evaluate changes in liabilities due to financing activities. To achieve this objective, the following changes in liabilities due to financing activities must be disclosed: (i) changes from financing cash flows; (ii) changes due to obtaining or losing control of subsidiaries or other businesses; (iii) the effect of changes in foreign exchange rates; (iv) changes in fair values; and (v) other changes. Financial liabilities are defined as liabilities "for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities." The new disclosure requirements also relate to changes in financial assets if they meet the same definition. One way to fulfill the new disclosure requirements is to provide a reconciliation between the opening and closing balances for liabilities due to financing activities. Finally, the amendments state that changes in liabilities due to financing activities must be disclosed separately from changes in other assets and liabilities. These amendments are effective for reporting periods beginning on or after January 1, 2017. Widespread EU adoption (endorsement) of these

amendments is expected for Q2 2017. As the amendment merely affects the presentation of the financial statement, it will have no impact on the net assets, financial position and earnings situation of the B. Braun Group.

IFRS 9, Financial Instruments

The IASB completed its project to replace IAS 39, Financial Instruments: Recognition and Measurement in July 2014 with the publication of the final version of IFRS 9, Financial Instruments. In its final version, IFRS 9 contains in particular fundamentally revised regulations on classifying and measuring financial instruments, accounting for the depreciation of financial assets, and hedge accounting relationships. For classifying and measuring financial assets, IFRS 9 provides the models "Hold to Achieve Contractual Cash Flows," "Hold and Sell" and "Intention to Trade" as a function of the company's business model. The classification and measurement rules for financial liabilities have changed very little through IFRS 9. The revised measurement rules for financial assets and liabilities will have no material effect on the net assets, financial position and earnings situation of the B. Braun Group. Due to the new rules governing accounting for depreciation, their recognition fundamentally changes, since not only incurred losses (current incurred loss model), but also expected losses (so-called expected loss model) are to be recognized, whereby the scope of recognition of expected losses is differentiated further based on whether or not the credit risk of financial assets has deteriorated markedly since their addition. The new rules on accounting for depreciation will also have no material effect on the net assets, financial position or earnings situation of the B. Braun Group. Also, the rules for hedge accounting have been completely revised. The primary aim of the new rules is to orient hedge accounting more strongly toward the company's economic risk management. A hedging relationship must therefore be maintained for accounting purposes as long as the documented risk management objective for this hedging relationship has not changed, and the other conditions for hedge accounting are met. Furthermore, individual risk components can be considered under IFRS 9 in isolation under certain conditions, even in non-financial transactions. In addition, the requirements for demonstrating the effectiveness of hedging transactions are changing. The B. Braun Group is currently reviewing the effects of the revised rules for hedge accounting on its net assets, financial position and earnings situation. IFRS 9 is effective for reporting periods beginning on or after January 1, 2018. In principle, the adoption must be applied retroactively, although various simplification options are granted. Earlier voluntary application is permitted, but the B. Braun Group will not elect to do so.

IFRS 15, Sales from Customer Contracts

On the one hand, the objective of the revised standards is, in particular, to unify the previous, less extensive regulations in the IFRS and, on the other, to standardize the very detailed and somewhat industry-specific regulations under US GAAP, thus improving the transparency and comparability of financial information. Under IFRS 15, sales are then realized when the customer obtains control of the agreed goods and services and can benefit from their use. The decisive factor is no longer a major transfer of risks and rewards, as under the old provisions of IAS 18, Revenue. Sales are to be valued as quid pro quo, that is, the compensation that the company expects to receive. The new model provides a five-step scheme for determining the revenue recognition, whereby in the first step the customer agreement and the separate performance obligations contained therein must be identified. Subsequently, the transaction price of the customer's contract shall be determined and divided up among the

individual obligations. Finally, revenue should be realized according to the new model for each performance obligation at the allocated pro rata transaction price as soon as the agreed service has been performed or the customer has obtained the power of disposal over it. A distinction that is based on predefined criteria is made here between point-in-time-related and period-of-time-based performance fulfillments. The new standard does not distinguish between different job and activity types, but establishes standardized criteria for when a service that is rendered should be realized as a point-in-time or period-of-time. In the future, IFRS 15 provisions will replace both the contents of IAS 18, Sales and IAS 11, Construction Contracts. In addition, a variety of other items are controlled for the first time and this could have implications for the current accounting policy, such as provisions for contract modifications or repurchase agreements. In September 2015, the IASB published an amendment to the standard postponing mandatory first-time application of the standard to reporting periods beginning on or after January 1, 2018. Voluntary early application of these requirements is permitted. In April 2016, some clarifications to IFRS 15 were published that primarily address the identification of separate performance obligations, principal versus agent considerations, and licensing. The B. Braun Group will apply a modified, retroactive version of the standard for the fiscal year starting on January 1, 2018, i.e., the standard will only retroactively apply to the most recent reporting period. For certain business models with multi-component contracts, the required separation of performance obligations and the resulting allocation of transaction price will likely alter the timeline for recording sales revenues. However, the amendments are expected to have no material impact on the net assets, financial position and earnings situation of the B. Braun Group.

IFRS 16, Leases

On January 13, 2016, the IASB published a new standard which fundamentally reforms the financial reporting of leases. Previously, all leases had been recognized either as finance leases or as operating leases. This distinction will cease to apply in the future for the lessee. Under the new standard, all leases are recognized in the balance sheet in the form of right-of-use assets and the financial liabilities, comparable to the existing procedure for finance leases. The relevant values are based on the present value of the minimum lease payments over the term of the lease. In the income statement, the lessee will disclose a depreciation charge for the lease assets and an interest expense on lease liabilities for each lease, in lieu of straight-line lease expenses. The disclosure of leases can only deviate from these rules if one of two possible exemptions applies (short-term leases and low-value leases). Unlike lessees, lessors will still have to classify leases as either finance leases or operating leases under IFRS 16. IFRS 16 is to be applied for the first time in reporting periods beginning on or after January 1, 2019. First-time application is generally to be retrospective, but various simplification options are available. Voluntary early application is permitted if IFRS 15 (revenue from contracts with customers) is also fully applied (early). EU adoption (endorsement) of these rules is expected for the second half of 2017. The B. Braun Group is currently reviewing the impact on the net assets, financial position, and earnings situation.

As part of the ongoing improvement project of the IFRS, adjustments to wordings for clarification and changes were also made. These have no major impact on the net assets, financial position, and results of operations of the B. Braun Group.

Aside from the standards described in detail above, the IASB has published additional standards/amendments to standards that do not affect the B. Braun Group:

Amendments to IAS 27, Separate Financial Statements – Equity Method in Separate Financial Statements: These apply to reporting periods beginning on or after January 1, 2016.

Amendments to IAS 16, Property, Plant and Equipment, and IAS 41, Agriculture – Bearer Plants: These apply to reporting periods beginning on or after January 1, 2016.

Amendments to IFRS 10, IFRS 12, and IAS 28, Investment Entities: Applying the Consolidation Exception: These apply to reporting periods beginning on or after January 1, 2016.

IFRS 14, Regulatory Deferral Accounts: This applies to reporting periods beginning on or after January 1, 2016; EU adoption (endorsement) of this rule still pending.

Amendments to IFRS 2, Share-based Payment: This applies to reporting periods beginning on or after January 1, 2018; EU adoption (endorsement) of this rule is still pending.

Critical Assumptions and Estimates for Accounting Policies

The preparation of financial statements in accordance with IFRS requires management to make assumptions and estimates that have an effect on the reported amounts and their related statements. While management makes these estimates to the best of its knowledge and abilities based on current events and measures, there is a possibility that actual results may differ. Estimates are necessary in particular when:

- Assessing the need for and the amount of write-downs and other value adjustments;
- Measuring pension obligations;
- Recognizing and measuring provisions;
- Establishing inventory provisions;
- Evaluating the probability of realizing deferred tax assets;
- Calculating the value in use of cash-generating units (CGU) for impairment testing.

The Group's management determines the expected useful life of intangible assets and property, plant and equipment, and therefore their depreciation or amortization, based on estimates. These assumptions can change materially, for example, as a result of technological innovations or changes in the competitive environment. Should their actual useful life be shorter than the estimate, management adjusts the amount of depreciation or amortization. Assets that are technologically outdated or no longer usable under the current business strategy are fully or partially written off.

The present value of pension obligations depends on a number of factors which are based on actuarial assumptions. The assumptions used for the calculation of net pension expenses (and income) include the applicable discount rate for pension obligations. Any change in such assumptions will have an effect

on the carrying amount of the pension provisions. Obligations from defined benefit pension plans, as well as pension expenses for the following year, are determined based on the parameters outlined under Note 25.

The method of determining interest rates is unchanged from the year before. An interest yield curve is derived from the analysis of corporate bonds. The discount rate is calculated by measuring a sample cash flow comparable to the circumstances of B. Braun, using the interest yield curve and deriving an equivalent standard discount rate.

The recognition and measurement of other provisions is based on estimates regarding the probability of a future outflow of resources, as well as experience and known circumstances as of the reporting date. The actual liability may differ from the amounts of the provisions established.

The estimate of inventory provisions is based on the projected net realizable value (i. e. the estimated selling price, less the estimated cost of completion and the estimated selling expenses). Actual sales and actual costs incurred may differ from these estimates.

Deferred tax assets are only recognized to the extent that it is probable that taxable profit will be available in the future. The actual taxable profits in future periods may differ from the estimates made on the date such deferred tax assets are capitalized.

Goodwill is tested for impairment annually based on a three-year forecast using projections of specific annual growth rates for the subsequent period. An increase or decrease in the projected annual growth rates would alter the estimated fair value of a given cash-generating unit.

Scope of consolidation

In addition to B. Braun Melsungen AG, the consolidated financial statements include 68 domestic and 195 foreign subsidiaries for which B. Braun Melsungen AG is exposed to variable returns and has the ability to influence them.

Subsidiaries are included in the consolidated financial statements effective on the day control is assumed by the Group. Consolidation is discontinued as of the day on which such control ends.

The change in the number of Group companies as of December 31, 2016 and 2015, respectively is shown below:

	2016	2015
Included as of December 31 of previous year	262	252
Companies included for the first time	7	20
Company consolidations discontinued	-4	-1
Business combinations	-2	-9
Companies now consolidated using the equity method due to the sale of shares	0	0
Included as of December 31 of reporting year	263	262

Deconsolidated companies had no material impact on the statement of financial position or the statement of income in fiscal year 2016.

The impact of company acquisitions on the statement of financial position at the time of initial consolidation and on the principal items in the statement of income for fiscal year 2016 is shown below:

	Carrying amount	Fair value
	€ '000	€ '000
Non-current assets	1,586	10,536
Current assets	1,380	1,380
Acquired assets	2,966	11,916
Non-current provisions and liabilities	0	0
Current provisions and liabilities	0	0
Acquired liabilities	0	0
Net assets acquired	2,966	11,916
Non-controlling interests	0	0
Prorated net assets	2,966	11,916
Goodwill		18,947
Cost of acquisition		30,671
of which non-controlling interests		(0)
Cash and cash equivalents acquired		0
Cash outflow from acquisitions		30,671
Sales		15,185
Operating profit		1,575
Consolidated net income		1,090

The total cost of acquisitions made during the fiscal year that were not significant individually or in aggregate was € 30.7 million and was paid in cash.

In the context of acquisitions, unrecognized assets in the amount of € 9.0 million have been recognized in the reporting year so far. Receivables amounting to € 0.9 million (gross € 0.9 million) were acquired. The goodwill remaining after purchase price allocation amounted to € 18.9 million. This amount is non-deductible and is largely attributable to sales and production synergies.

If all of the acquisitions had been made at the start of the current fiscal year, the Group's sales would have been € 19.3 million higher. After-tax earnings would have been € 4.4 million higher.

The acquisitions made during the fiscal year relate primarily to the expansion of the dialysis center network of the B. Braun Avitum division in Germany and the expansion of product offerings in South Africa.

On January 1, 2016, two nephrology clinics in Oldenburg and Suhl were acquired in asset deals. On April 1, 2016, two more nephrology clinics in Landau and Wolfenbüttel were acquired in asset deals. These acquisitions strengthened our network of dialysis centers in Germany.

On July 1, 2016, the businesses Dismed Pharmaceutical (Pty) Ltd and Dismed Criticare (Pty) Ltd in South Africa were acquired in an asset deal. The businesses specialize in the production of hand disinfectants and infusion solutions. This acquisition further expanded our offering of medical and pharmaceutical products in South Africa and strengthened our position as a system partner in South Africa.

On October 10th, 2016, another 45.97 percent of shares in Sialy Ser S.A.S. in Columbia were acquired. The purchase price was € 4.7 million. The B. Braun Group now holds 94.0 percent of shares. The carrying value of the acquired, non-controlling interest at the time of acquisition was € 1.1 million. The difference of € 5.9 million was recognized in the Group's equity.

These changes did not adversely impact the comparability of the financial statements with those of the previous year.

Holdings in two joint ventures and 20 associated companies are recognized in the consolidated financial statements as of the reporting date. Three associated companies were not measured using the equity method on materiality grounds.

REVIUM Rückversicherung AG is included in the consolidated financial statements of B. Braun Melsungen AG as a wholly-owned subsidiary. The only business purpose of REVIUM Rückversicherung AG is to arrange reinsurance with companies (direct insurers) with which B. Braun Melsungen AG has taken out insurance contracts. It does not arrange any insurance contracts with third parties that extend beyond this and does not cover risks outside of the B. Braun Group. Due to its narrowly defined business purpose, REVIUM Rückversicherung AG has no material impact on the net assets, financial position, and earnings situation of the B. Braun Group as a whole.

As part of an asset-backed securities program, trade receivables for individual Group companies are assigned to a structured unit. This structured unit shall not be consolidated in the B. Braun Melsungen AG consolidated financial statements. Please see Note 18 for further information.

The complete list of shareholdings belonging to the Group and to B. Braun Melsungen AG is provided in Notes to the consolidated financial statements.

The following companies are included in the consolidated financial statements of B. Braun Melsungen AG:

- B. Braun Facility Services GmbH & Co. KG, Melsungen,
- Hansepharm GmbH & Co. KG, Roth,
- Invitec GmbH & Co. KG, Duisburg,
- MAT Adsorption Technologies GmbH & Co. KG, Eisenfeld,
- medical experts online GmbH & Co. KG, Melsungen.

They meet the conditions of Section 264 b of the German Commercial Code (HGB) and are thus exempted from the requirement to compile Notes and a management report as well as the publishing of financial statements.

The following companies meet the conditions of Section 264 (3) of the German Commercial Code (HGB) and are thus also exempted from the requirement to compile Notes and a management report as well as the publishing of financial statements:

- Aesculap AG, Tuttlingen,
- Aesculap Akademie GmbH, Tuttlingen,
- Aesculap International GmbH, Tuttlingen,
- Aesculap Suhl GmbH, Suhl,
- Avitum Transcare Germany GmbH, Melsungen,
- BBM Group Insurance Broker GmbH, Melsungen,
- B. Braun Medical AG, Melsungen,
- B. Braun Avitum AG, Melsungen,
- B. Braun Avitum Saxonia GmbH, Radeberg,
- B. Braun IT Service GmbH, Melsungen,
- B. Braun Surgical GmbH, Melsungen,
- B. Braun Petzold GmbH, Melsungen,
- B. Braun Mobilien GmbH, Melsungen,
- B. Braun Nordamerika Verwaltungsgesellschaft mbH, Melsungen,
- B. Braun International GmbH, Melsungen,
- B. Braun TravaCare GmbH, Hallbergmoos,
- B. Braun Vertriebs GmbH, Melsungen,
- B. Braun VetCare GmbH, Tuttlingen,
- Bibliomed medizinische Verlagsgesellschaft mbH, Melsungen,
- Inko Internationale Handelskontor GmbH, Roth,
- Nierenzentrum Bad Kissingen MVZ, GmbH, Bad Kissingen,
- Nutrichem diät + pharma GmbH, Roth,
- Paul Müller Technische Produkte GmbH, Melsungen,
- PNS Professional Nutrition Services GmbH, Melsungen,
- SteriLog GmbH, Tuttlingen,
- Transcare Gesundheitsservice GmbH, Melsungen.

The companies listed above exercise their right to the exemptions.

PRINCIPLES OF CONSOLIDATION

a) Subsidiaries

Subsidiaries, that is, such corporations that are controlled by B. Braun Melsungen AG, are included in the scope of consolidation. B. Braun Melsungen AG controls an entity when it is exposed to variable returns from its involvement with the investee, has entitlements to these and has the ability to affect those returns through its power over the investee.

Subsidiaries are initially consolidated on the first day on which B. Braun Melsungen AG assumes right of disposal of the acquired company; they are excluded from consolidation once B. Braun Melsungen AG forfeits such control. Right of disposal occurs when B. Braun Melsungen AG has the ability to direct the relevant activities of the investee because it possesses the majority of the voting rights or other contractual rights. The acquisition of subsidiaries is recognized using the purchase method. The cost of

acquiring a subsidiary is calculated based on payments of cash and cash equivalents, together with the fair value of assets transferred, shares issued, and/or liabilities acquired when initial control is gained. Acquisition-related costs for a business combination are expensed. Conditional purchase price components are recognized at fair value on the date of acquisition. Subsequent changes in the fair value of the contingent purchase price liability are recognized in profit or loss or in other comprehensive income. Acquisition costs that exceed the proportionate acquired share of the fair value of the subsidiary's net assets are recognized as goodwill.

Assets, debts, and contingent liabilities identifiable upon a merger of companies are valued on initial consolidation at the fair values attributable to them, regardless of the size of any non-controlling interests. For each company acquisition, it is determined on an individual basis whether the non-controlling interests in the company acquired are recognized at fair value or using the proportionate share of net assets of the acquired company. The option to recognize non-controlling interests at fair value is currently not exercised. Therefore, non-controlling interests are recognized at their proportionate share of net assets, and no goodwill is recognized for non-controlling interests.

Goodwill generated by the acquisition of non-controlling interests in fully consolidated companies is offset against retained earnings. Where assets and liabilities are measured at fair value for the gradual acquisition of companies fully consolidated for the first time, the revaluation of the "old" tranches is recognized through profit or loss.

Intercompany receivables and payables, as well as expenditure and income, are offset against each other. Unrealized gains on transactions between companies within the Group are eliminated in full; unrealized losses are eliminated insofar as the resulting costs of acquisition or manufacture do not exceed the recoverable amount of the underlying asset. The recoverable amount is the higher of an asset's fair value less costs to sell or its value in use.

Subsidiary companies' accounting policies are, where necessary, adapted to those used to produce the consolidated financial statements.

b) Associated companies

Associated companies are those companies over which the Group has significant influence but no control, generally accompanied by a holding of 20–50 percent of the voting rights. Investments in associates are accounted for using the equity method and are initially recognized at cost. The Group's investment in associated companies includes goodwill identified on acquisition (net of any accumulated impairments).

The Group's share of associated companies' post-acquisition profits or losses is recognized in the statement of income, and its share of post-acquisition changes in retained earnings is recognized in the Group's retained earnings. The cumulative post-acquisition changes are adjusted against the carrying amount of the investment. When the Group's share of losses in an associated company equals or exceeds its interest in the associated company, including any other unsecured receivables, the Group does not

recognize further losses unless it has incurred obligations or made payments on behalf of the associated company.

Unrealized gains from transactions between the Group and its associated companies are, where material, eliminated to the extent of the Group's share in the associate. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of associated companies were adjusted, where necessary, to align them with the policies of the Group.

c) Joint agreements

Investments in joint agreements are classified as either a joint operation or a joint venture. The B. Braun Melsungen AG joint agreements represent joint ventures. These are included in the consolidated financial statements using the equity method. The shares are initially recognized at cost and subsequently updated in order to reflect the Group's share in the profits and losses in other comprehensive income. When the Group's share of losses in a joint venture equals or exceeds its interest in this company, including any other unsecured receivables, the Group does not recognize further losses unless it has incurred obligations or made payments on behalf of the joint venture company. Unrealized gains arising from transactions with joint ventures are eliminated in the amount equal to the Group's share. Unrealized losses are also eliminated unless the transferred assets are impaired.

d) Owners of non-controlling interests

Transactions with owners of non-controlling interests are treated in the same way as transactions with parties within the Group. Sales of shares to owners of non-controlling interests result in gains or losses being recognized in the consolidated financial statements. Reciprocally, purchases of shares from owners of non-controlling interests result in the recognition of goodwill equivalent to the difference between the purchase price and the proportional carrying amount of the subsidiary's net assets.

FOREIGN CURRENCY TRANSLATION

a) Functional and reporting currency

Items included in the financial statements of each of the Group's subsidiaries are stated using the currency of the primary economic environment in which the company operates (functional currency).

The consolidated financial statements are stated in euros, that being the Group's functional and reporting currency.

b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the prevailing exchange rate on the date of the transaction. Foreign exchange losses and gains resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign

currencies at the exchange rates prevailing on the reporting date are recognized in the statement of income.

Translation differences on monetary items, such as equities classified as available-for-sale financial assets, where fair value changes are directly recognized in equity, are reported as part of the gain or loss from fair value measurement. On the other hand, translation differences on non-monetary items, where fair value changes are directly recognized in equity, are included in the revaluation reserve in equity.

c) Subsidiaries

All items in the statements of income and statements of financial position of all Group subsidiaries that are in a currency other than the Group reporting currency are translated into the reporting currency as follows:

- Assets and liabilities are translated at the closing rate on the reporting date;
- income and expenses are translated at average exchange rates; and
- all resulting exchange differences are recognized as a separate component of equity (effects of foreign currency translation).

Goodwill and fair value adjustments arising from the acquisition of foreign companies are treated as assets and liabilities of the foreign company and translated at the closing rate.

Upon the sale of a foreign business operation, currency differences formerly recognized in equity are taken to the statement of income as gains or losses on disposal.

COMPARISON OF SELECTED CURRENCIES

ISO code	Closing mid-rate on reporting date			Average annual rate		
	Dec. 31, 2016	Dec. 31, 2015	+ – in %	2016	2015	+ – in %
1 EUR = USD	1.056	1.089	-3.0	1.107	1.110	-0.3
1 EUR = GBP	0.859	0.735	16.8	0.819	0.726	12.8
1 EUR = CHF	1.075	1.082	-0.7	1.090	1.068	2.1
1 EUR = MYR	4.737	4.676	1.3	4.584	4.332	5.8
1 EUR = JPY	123.510	131.120	-5.8	120.304	134.285	-10.4

ACCOUNTING POLICIES

Intangible assets

a) Goodwill

Goodwill represents the excess of the cost of an acquisition over the fair value of identifiable net assets and liabilities of the acquired company on the date of the acquisition. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill on acquisitions of associates is included in the carrying amount for investments in affiliates. Goodwill is tested for impairment at least once a year and is

carried at cost less accumulated impairment losses. Write-downs of goodwill are reported under other operating expenses. Write-ups in value are not permitted. Gains and losses on the sale of companies include the carrying amount of the goodwill relating to the company sold.

b) Development costs

The B. Braun Group invests a significant portion of its financial assets in research and development. In addition to internal research and development activities, the Group maintains numerous cooperative relationships with third parties.

Development expenses are defined as costs related to applying research findings or specialized knowledge for production planning and the manufacturing process before production or use has commenced. Development expenses are capitalized as intangible assets where it is regarded as likely that the project will be commercially successful and technically feasible, and the costs can be reliably measured. Other development costs that do not meet these criteria are expensed as they occur. Development costs that have previously been expensed are not capitalized in subsequent years. Capitalized development costs are shown as internally created intangible assets. Please see c below regarding the useful life, amortization method, and review of residual carrying amounts.

C) Other intangible assets

Acquired intangible assets are recognized at acquisition cost. Internally developed intangible assets where future economic benefit is likely to flow to the Group and the costs of the asset can be reliably measured are recognized at the cost incurred during the development phase. This includes all costs directly related to the development process, as well as appropriate portions of relevant overhead costs. Intangible assets with finite useful lives are amortized by the straight line method over a period of four to eight years. The defined benefit amortization method is used for reasonable exceptions.

Residual carrying amounts and expected useful lives are reviewed at each reporting date and adjusted if necessary.

A write-down is taken at the reporting date if the recoverable amount of an intangible asset falls below its carrying amount.

Amortization expense related to other intangible assets is recognized in the functional areas that are using the respective asset. Write-ups to a maximum of amortized acquisition or manufacturing cost are shown under other operating income.

Intangible assets with indefinite useful lives, if present, are tested for impairment at least once a year. Besides goodwill, the Group did not own any intangible assets with indefinite useful lives in the reporting periods presented.

Impairment of non-financial assets

At each reporting date, the carrying amounts of intangible assets and property, plant and equipment are evaluated for indications of impairment. Where there is such an indication, an impairment test is conducted by comparing the carrying amount of the asset in question with its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or its value in use (net present

value of expected free cash flows). The test can be conducted for a cash-generating unit (CGU) where the recoverable amount cannot be determined because the asset does not generate cash inflows that are largely independent of those from other assets. If an asset's recoverable amount is less than its carrying amount, an impairment is recognized through profit and loss. This impairment can be reversed through profit and loss at a later point in time if the recoverable amount of the asset is later found to be higher. However, the increased carrying amount due to reversal may not be higher than what it would have been if the impairment had not been recognized.

Property, plant, and equipment

Tangible assets that are utilized during the ordinary course of business for more than one year are recognized at their acquisition or manufacturing cost less depreciation using the straight line method. The manufacturing costs include all costs directly related to the manufacturing process and appropriate portions of relevant overhead costs. Scheduled depreciation of property, plant and equipment is based on the straight-line method, in which the cost will be recognized over the estimated useful life until the residual value is reached. The useful lives applied correspond to the expected useful lives within the Group. The defined benefit amortization method is used for reasonable exceptions.

The following useful lives are the basis for depreciation of property, plant, and equipment:

Buildings	25 to 50 years
Technical plant and machinery*	5 to 20 years
Vehicles	6 years
Operating and office equipment	4 to 20 years

* 1-shift operation

Land is not depreciated.

Acquisition and manufacturing costs that are incurred at a later point are recognized as part of the asset or as a separate asset only when it is likely that the future economic benefits associated with the asset will flow to the Group and that the cost of the asset can be reliably measured. All other repairs and maintenance are reported as expenses in the statement of income of the fiscal year in which they occur.

Residual carrying amounts and expected useful lives are reviewed at each reporting date and adjusted if necessary.

A write-down is taken at the reporting date if the recoverable amount of an item of property, plant and equipment falls below its carrying amount.

Depreciation expense related to property, plant and equipment is recognized in the functional areas that are using the respective asset. Write-ups to a maximum of amortized acquisition or manufacturing cost are shown under other operating income. Gains and losses from disposals of property, plant and equipment are recognized in the statement of income.

Government grants are recognized at fair value if receipt of the grant and the Group compliance with any conditions associated with the grant are highly likely.

Outside borrowing costs directly attributable to the acquisition, construction, or development of a qualifying asset are recognized as part of its acquisition or manufacturing cost.

Finance leasing

Leasing contracts for intangible assets and property, plant and equipment, where the Group carries the substantial risks and rewards of ownership of the leased asset, are classified as finance leases. At commencement of the lease term, finance leases are recognized as an asset at the lower of the fair value of the asset or the net present value of the minimum lease payments. Each leasing payment is apportioned between the finance charge and the reduction of the outstanding liability, so as to produce a constant periodic rate of interest on the leasing liability. This liability is reported under financial liabilities excluding the interest payments. The interest portion of the leasing payment is recognized as expense through the statement of income. Assets held under finance leases are depreciated over the useful life of the asset. If there is no reasonable certainty that the Group will obtain ownership of an asset at the end of the lease, the asset is depreciated in full over the shorter of the lease term or the useful life of the asset.

Financial investments recognized using the equity method of accounting and other financial investments

Equity investments are initially recognized at cost and in subsequent periods at the amortized prorated net assets. The carrying amounts are increased or decreased annually by the share in profit, distributions and other changes in equity. Goodwill is not reported separately, but is included in the value of participation. Goodwill is not amortized. Equity investments are written down when the recoverable amount of an investment in an associate falls below its carrying amount.

Categories of financial assets

Financial assets are classified using the following categories:

- Financial assets at fair value through profit and loss,
- Loans and receivables,
- Held-to-maturity financial assets,
- Available-for-sale financial assets.

The categorization depends on the purpose for which the assets were acquired. Management determines the categorization of financial assets at initial recognition and re-evaluates this categorization on each reporting date.

a) Financial assets at fair value through profit and loss

Financial assets are measured at fair value through profit and loss if the financial asset is either held for trading or designated as being measured at fair value.

A financial asset is classified as held for trading if it has been acquired principally for the purpose of earning profits from short-term price changes. This category also includes derivatives that have not been designated as hedging instruments.

To date, the Group has not exercised the option of designating financial assets upon initial recognition as financial assets at fair value through profit and loss.

b) Loans and receivables

Loans and receivables with fixed or determinable payments that are not quoted on an active market are categorized as loans and receivables. At initial recognition, loans and receivables are measured at fair value plus transaction costs. They are subsequently measured using the effective interest method at amortized cost less any impairments. With the exception of current receivables, where the interest rate effect is not material, interest income is recognized using the effective interest method.

c) Held-to-maturity financial assets

Bills of exchange and debt instruments with fixed or determinable payments and fixed maturities, which the Group has the intention and ability to hold to maturity, are categorized as "investments held-to-maturity." At initial recognition, held-to-maturity investments are measured at fair value plus transaction costs. They are subsequently measured at amortized cost using the effective interest method less impairments.

d) Available-for-sale financial assets

Listed shares and redeemable bonds held by the Group that are traded on an active market are recognized as available-for-sale financial assets and, at initial recognition, are measured at fair value plus transaction costs. Investments in unlisted shares held by the Group that are not traded on an active market are also recognized at fair value as available-for-sale financial assets, to the extent that this can be reliably measured. Otherwise, they are subsequently measured at the cost of acquisition. Gains and losses arising from changes in fair value are included directly in the revaluation reserve (equity) rather than in other net financial income. Exceptions are impairment losses, interest calculated using the effective interest method, and income and expenses from foreign currency translation of monetary items, which are recognized in the income statement. If a financial asset is disposed of or is acknowledged to have an impairment, its accumulated gains and losses recognized in the revaluation reserve for financial investments up to that point are reclassified as profits or losses.

Dividends from equity instruments classified as available-for-sale financial assets are recognized in the statement of income as soon as the Group has acquired a right to the dividend.

Impairment of financial assets

With the exception of financial assets measured at fair value through profit and loss, financial assets are examined at each reporting date for the presence of any indications of impairment. Financial assets are considered impaired if, following one or more events that occurred after the initial recognition of the asset, there is objective evidence that the estimated future cash flows of the investment have changed adversely.

In the case of listed and unlisted equity investments that were categorized as available-for-sale, any significant or prolonged reduction in the fair value of the assets below their acquisition cost must be regarded as objective evidence of impairment.

For all other financial assets, the following may be objective evidence of impairment:

- Either the issuer or the counterparty is facing significant financial difficulties,
- Default or delinquency in payments of interest or principal, and
- A high probability that the debtor will enter bankruptcy or financial reorganization.

For some classes of financial assets, such as trade receivables, asset values for which no impairment has been determined on an individual basis are tested for impairment on a portfolio basis. Objective evidence of impairment on a portfolio of receivables is based on the past experience of the Group regarding payments received, an increase in the frequency of payment defaults within the portfolio over the average borrowing period, and observable changes in the national or local economic environment with which the defaults can be linked.

In the case of financial assets valued at amortized cost, the impairment loss corresponds to the difference between the carrying amount of the asset and the net present value of expected future cash flows determined on the basis of the original effective interest rate on the asset.

An impairment leads to a direct reduction in the carrying amount of all the relevant financial assets, with the exception of trade receivables, whose carrying amount is reduced through a valuation adjustment account. If a trade receivables item is considered to be irrecoverable, it is written off against the valuation adjustment account. Changes in the carrying amount of the valuation adjustment account are recognized in the statement of income.

In the event that a financial asset, classified as available-for-sale, is considered to be impaired, gains and losses previously recognized in the revaluation reserve (equity) are reclassified to the statement of income in the period in which the impairment occurred.

If the level of impairment of a financial asset that is not an available-for-sale equity instrument decreases in a subsequent reporting period, and if the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment is reversed through the statement of income. The increased carrying amount due to reversal may not be higher than what the amortized cost would have been if the impairment had not been recognized.

In the case of equity instruments classified as available-for-sale, any impairments recognized in the past are not reversed. Any increase in the fair value after an impairment was recognized is recorded in the revaluation reserve (equity).

Inventory

Under IAS 2, inventories include assets that are held for sale in the ordinary course of business (finished products and merchandise), assets that are in the production process for sale in the ordinary course of

business (work in progress), and assets that are consumed in the production process or performance of services (raw materials and supplies). Inventories are measured at the lower of cost and net realizable value, which is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated selling expenses, applying the weighted average cost formula. Related to this, the risks, in particular those arising from the storage period, reduced usability, etc., are taken into account by means of devaluations.

In addition to direct expenses, manufacturing costs include allocated raw material and production overheads and depreciation related to production plant and equipment. Allocated costs related to pensions and voluntary social contributions made by the company are also included. Administrative expenses are included in the costs if they relate to manufacturing.

Provisions for pensions and similar obligations

Our actuary calculates provisions for pensions and similar obligations using the projected unit credit method in accordance with IAS 19, taking into account future pay and pension increases and staffing fluctuations. Revaluations of net financial debt are recognized in equity in the period in which they occur.

Net interest on net financial debt is reported under financial income.

Any excess of plan assets over the pension obligations is recognized as an asset only if it represents the net present value of the economic benefits.

Other provisions

Provisions are recognized when a present legal or constructive obligation has arisen for the Group as a result of a past event, an outflow of resources to settle the obligation is likely, and the amount can be estimated reliably. If a number of obligations of a similar type exist, the provisions are recognized at the most probable value for the population of events.

Provisions are recognized for onerous contracts if the expected benefit from the contractual claim is less than the expected costs to settle the obligation. Any associated assets are tested for impairment before such a provision is created.

Provisions due after more than one year are measured at discounted present value.

Provisions are released against the expense items for which they were created. If additions to provisions were recognized under other operating expenses, the release of these amounts is shown under the corresponding other operating income item.

Financial Debt

Financial liabilities are initially recognized at fair value less transaction costs. In subsequent periods, they are measured at amortized cost. Any difference between the amount disbursed (less transaction costs) and the repayment amount is spread across the term of the loan using the effective interest method and recognized in the statement of income.

Liabilities from loans are recognized as current liabilities unless the Group has the unconditional right to defer repayment of the liability to at least 12 months after the reporting date.

Liabilities

Financial liabilities comprise trade accounts payable and other liabilities, and are initially recognized at fair value less transaction costs.

Current liabilities have a residual maturity of up to one year and are stated at their repayment or settlement amount. Non-current liabilities that are not the underlying transaction in permissible hedge accounting are recognized at the cost of acquisition.

Accruals and deferrals are recognized under other liabilities.

Derivative financial instruments

Derivative financial instruments are recognized using trade date accounting. They are initially measured at their fair value on the date the contract is entered into. They are subsequently measured at their fair value as of each reporting date. The method of recording gains and losses depends on whether the derivative financial instruments in question have been designated as hedging instruments and, if so, on the nature of the hedged item. On entering into a transaction, the Group documents the hedge relationship between the hedging instrument and the underlying transaction, the goal of its risk management, and the underlying hedging strategy. In addition, the assessment of whether the derivatives employed effectively compensate for the changes in the fair values or in the cash flows of the underlying transactions is documented at the time the hedging relationship is created and subsequently on an ongoing basis. The fair values of the various derivative financial instruments used for hedging purposes are recognized under other assets/liabilities. Changes in the valuation reserve for cash flow hedges are shown in the consolidated statement of changes in equity. The full fair value of derivative financial instruments designated as hedge instruments is shown as a non-current asset or liability if the residual term of the hedged underlying transaction is more than 12 months after the reporting date, and as a current asset or liability if it is shorter than that. Derivative financial instruments held for trading are recognized as current assets or liabilities unless the residual term is more than 12 months, in which case they are recognized as non-current assets or liabilities.

When a hedging transaction designated as a cash flow hedge expires or sold, or the designation is deliberately reversed or no longer meets the criteria to be accounted for as a hedging transaction, gains or losses accumulated in equity up to that point remain in equity and are only taken to the statement of income when the future transaction originally hedged occurs and is recognized in the statement of income. If the future transaction is no longer expected to occur, gains or losses accumulated in equity must be immediately reclassified to the income statement.

Certain derivative financial instruments are not eligible for hedge accounting. Note 32 provides additional explanatory information about the use of derivative financial instruments as part of risk management.

Deferred taxes

Deferred taxes are recognized using the liability method for all temporary differences between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements, unless deferred tax arises from the initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither the balance sheet result nor the taxable period result. Deferred taxes are measured using tax rates and laws that have been enacted or substantially enacted as of the reporting date and are expected to apply when the related deferred tax assets are realized or the deferred tax liabilities are settled.

Deferred tax assets stem primarily from temporary differences between the tax bases of individual companies and the financial statements set forth using IFRS, and from consolidation. Deferred tax assets stemming from losses carried forward and tax credits are recognized to the extent that it is likely that future taxable income will be available against which the losses carried forward can be utilized.

Deferred tax liabilities arising from temporary differences in connection with investments in subsidiaries and associates are recognized except where the timing of the reversal of the temporary differences can be controlled by the Group and it is likely that the temporary differences will not be reversed in the foreseeable future. Please also see Note 10, "Income Taxes."

NOTES ON THE CONSOLIDATED STATEMENT OF INCOME (LOSS)

1 Sales

Sales include the fair value received for the sale of goods and services excluding sales tax, rebates and discounts, and after eliminating intercompany sales. Sales are recognized as follows:

Sales resulting from the sale of products are recorded when the main risks and rewards associated with ownership have been transferred to the buyer and the collection of the associated receivables can be assumed with sufficient likelihood.

Estimates for sales reductions are based on experience. Adjustments are made if required by a change in conditions. No significant returns were recorded in the reporting period.

Sales resulting from the sale of services are recorded in the fiscal year during which the service is performed using the percentage of completion basis.

The following chart shows sales trends by division, region and type:

Sales by division	2016		2015		+ – in %
	€ '000	%	€ '000	%	
Hospital Care	2,990,791	46.2	2,855,924	46.6	4.7
Aesculap	1,724,994	26.7	1,662,905	27.1	3.7
OPM	781,654	12.1	740,611	12.1	5.5
B. Braun Avitum	944,803	14.6	846,256	13.8	11.6
Other sales	28,736	0.4	24,074	0.4	19.4
	6,470,978	100.0	6,129,770	100.0	5.6

Sales by region	2016		2015		+ – in %
	€ '000	%	€ '000	%	
Germany	1,096,657	16.9	1,035,239	16.9	5.9
Europe	2,070,653	32.0	1,999,285	32.6	3.6
North America	1,536,115	23.7	1,428,257	23.3	7.6
Asia-Pacific	1,162,878	18.0	1,073,426	17.5	8.3
Latin America	400,238	6.2	391,089	6.4	2.3
Africa and the Middle East	204,437	3.2	202,474	3.3	1.0
	6,470,978	100.0	6,129,770	100.0	5.6

Sales by type	2016		2015		+ – in %
	€ '000	%	€ '000	%	
Sales of products	5,684,729	87.8	5,431,627	88.6	4.7
Sales of services	786,249	12.2	698,143	11.4	12.6
	6,470,978	100.0	6,129,770	100.0	5.6

2 Cost of goods sold

Cost of goods sold includes the manufacturing costs of goods sold and the acquisition costs of merchandise sold. In addition to direct costs such as material, personnel and energy costs, manufacturing costs contain production-related overhead expenses, including depreciation of property, plant and equipment. Cost of goods sold also includes inventory write-downs.

3 Selling expenses

Selling expenses include expenditures for marketing, sales organizations and distribution. This category also contains the expenses related to customer training and consulting on technical product use.

4 Research and development expenses

Research and development expenses include costs for research, as well as for product and process development, including expenditures for external services. All research costs are expensed at the time they are incurred.

Development costs are capitalized where all the conditions for capitalization under IAS 38 are met.

5 Other operating income

	2016 € '000	2015 € '000
Currency translation gains	244,093	335,692
Additional income	18,431	18,044
Derivative financial instruments	4,026	21,526
Income from other periods	4,215	4,660
Proceeds from appreciation of current financial assets	1,422	2,502
Proceeds from the disposal of assets	1,926	2,792
Proceeds from the release of provisions	924	1,582
Other	24,746	24,101
	299,783	410,899

Currency gains primarily include gains from currency fluctuations between transaction and payment days from receivables and payables denominated in foreign currencies, as well as gains resulting from translation at the exchange rate prevailing on the reporting date. Starting this fiscal year, the gains and losses from cash flow hedges that were initially recognized in equity are no longer transferred to other operating income/expenses, rather to costs of goods sold. Figures from the previous year were adjusted accordingly by € 14.6 million.

Ancillary revenues include, in particular, revenues from the sale of put options, cost reimbursements from third parties and revenue from cafeteria sales.

Changes in the fair value of forward foreign exchange contracts that are not designated for hedge accounting are reported under derivative financial instruments.

Other operating income includes primarily payments of damages as well as government grants related to income statement and miscellaneous items. Income-related grants are recognized in the period in which the corresponding expenses occur. These amounted to € 1,277,000 (previous year: € 537,000). During the fiscal year, grants of € 620,000 (previous year: € 510,000) were recognized through profit and loss. The grants were predominantly made to support structurally weak areas in Germany.

Other income includes numerous types of income; however, their individual valuations are not materially significant.

6 Other operating expenses

	2016 € '000	2015 € '000
Currency translation losses	236,136	376,190
Losses from impairment of current financial assets	9,215	16,728
Additions to provisions	3,891	5,243
Losses on the disposal of assets	6,608	6,359
Expenses from other periods	5,247	6,115
Derivative financial instruments	26,865	3,466
Other	41,924	46,308
	329,886	460,409

Currency losses primarily include losses from currency fluctuations between transaction and payment days from receivables and payables denominated in foreign currencies, as well as losses resulting from translation at the exchange rate prevailing on the reporting date.

Losses from impairment of current financial assets refer to value adjustments to trade receivables.

Changes in the fair value of forward foreign exchange contracts that are not designated for hedge accounting are reported under derivative financial instruments.

Other expenses include numerous types of expenses; however, their individual valuations are not materially significant.

7 Financial investments recognized using the equity method of accounting

Net income from investments recognized using the equity method of accounting breaks down as follows

	2016 € '000	2015 € '000
Income from financial investments recognized using the equity method	19,264	19,093
Expenses from financial investments recognized using the equity method	- 1,540	- 180
	17,724	18,913

8 Net financial income

	2016 € '000	2015 € '000
Interest and similar income	6,436	5,198
Interest and similar expenses	- 46,620	- 50,013
of which to affiliated companies	(0)	(0)
Interest expenses for pension provisions, less expected income from plan assets	- 29,430	- 26,612
	- 69,614	- 71,427
of which financial assets and liabilities not measured at fair value through profit and loss:		
Interest income from discounting	(971)	(1,144)
Accrued interest expense	(- 2,547)	(- 2,833)

Interest and similar expenses are primarily comprised of interest expense on financial liabilities. Expenses resulting from accruing interest from non-current other provisions are also recognized here.

9 Other net financial income

	2016 € '000	2015 € '000
Income from joint ventures (excluding income from financial investments recognized using the equity method)	80	15,191
Other net financial income	- 2,589	- 18
	- 2,509	15,173

Interest on derivative financial instruments is shown under net interest income.

10 Income taxes

Income taxes include corporation tax and trade income taxes for German companies as well as comparable income-related taxes for companies in other countries. They are calculated on the basis of the tax regulations applicable to the individual company.

Deferred taxes stem from temporary differences between the tax base of the individual companies and the consolidated statement of financial position. They are measured using the liability method based on the application of anticipated future tax rates for the individual countries as of the realization date. Generally, these are based on the regulations in effect as of the reporting date. Deferred tax assets are offset only if the company has the legal right to settle current tax assets and current tax liabilities on a net basis and they are levied by the same tax authority. Income tax expenses and deferred taxes are as follows:

	2016 € '000	2015 € '000
Actual income taxes	151,780	123,536
Deferred taxes resulting from temporary differences	- 1,299	3,851
Deferred taxes resulting from losses carried forward and tax credits	- 18,710	- 1,585
	131,771	125,802

Deferred tax assets and deferred tax liabilities apply to differences stemming from recognition and measurement in the following items in the statement of financial position:

	Dec. 31, 2016		Dec. 31, 2015	
	Assets € '000	Liabilities € '000	Assets € '000	Liabilities € '000
Intangible assets	9,964	56,400	8,635	49,553
Property, plant, and equipment	6,454	209,897	4,294	193,260
Financial assets	198	8,051	491	8,036
Inventories	83,825	8,513	75,486	8,656
Trade accounts receivable	7,862	10,518	7,568	10,013
Pension provisions	221,358	325	165,536	368
Other provisions	28,136	867	24,163	863
Liabilities	60,941	434	53,308	534
Other items	355	2,595	17	3,474
	419,093	297,600	339,498	274,757
of which non-current	(263,027)	(279,101)	(201,641)	(256,226)
Net balance	- 188,899	- 188,898	- 175,017	- 175,017
	230,194	108,702	164,481	99,740
Valuation allowance on deferred tax assets from temporary differences	- 148	-	- 922	-
Deferred taxes on tax credits	42,458	-	29,387	-
Losses carried forward (net, after valuation allowances)	16,112	-	10,493	-
	288,616	108,702	203,439	99,740

The amount of temporary differences related to holdings in subsidiaries and associates, as well as interests in joint ventures for which, according to IAS 12.39, no deferred tax liabilities were recognized, is € 20,000 (previous year: € 4,557,000).

Existing but not recognized tax losses carried forward can be used as follows:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Within one year	444	347
Within two years	539	378
Within three years	495	4,889
Within four years	463	0
Within five years or longer	5,292	3,714
	7,233	9,328
Can be carried forward indefinitely	74,062	67,029
	81,295	76,357

Deferred tax assets for which utilization depends on future taxable profits in excess of the profits arising from the reversal of existing taxable temporary differences, and where the company has incurred past losses, amounted to € 16,165,000 (previous year: € 6,655,000). Recognition of these deferred tax assets is based on relevant forecasting, which justifies the expectation that they will be used.

Deferred taxes of € 180,873,000 (previous year: € 125,321,000) were recognized directly in equity. This amount was primarily comprised of actuarial gains and losses related to pension obligations, totaling € 166,835,000 (previous year: € 115,502,000), of changes in the fair value of securities, totaling –€ 11,000 (previous year: –€ 11,000), and of changes in the fair value of derivative financial instruments designated as cash flow hedges, totaling € 3,338,000 (previous year: € 1,278,000).

The tax rate for B. Braun Melsungen AG is 29.0 percent (previous year: 29.0 percent). The tax expense which is calculated using B. Braun Melsungen AG's tax rate can be reconciled to actual tax expense as follows:

	2016 € '000	2015 € '000
Tax rate of B. Braun Melsungen AG	29.0%	29.0%
Profit before tax	527,773	445,519
Expected income tax at parent company's tax rate	– 153,054	– 129,201
Differences due to other tax rates	10,435	6,745
Changes to deferred tax assets and liabilities due to changes in tax rates	– 576	1,515
Tax reductions due to tax-exempt income	21,684	26,766
Tax increases due to non-deductible expenses	– 18,655	– 23,398
Addition/deduction of trade tax and similar foreign tax items	– 1,502	– 1,861
Final withholding tax on profit distributions	– 880	– 1,567
Tax credits	14,442	4,110
Tax expense relating to previous periods	– 945	– 577
Change to valuation allowances on deferred tax assets	– 1,175	– 11,248
Profit (loss) of financial investments recognized using the equity method	1,312	1,375
Other tax effects	– 2,857	1,539
Actual tax expense	– 131,771	– 125,802
Effective tax rate	25.0%	28.2%

11 Earnings per share

Earnings per share are calculated according to IAS 33 by dividing the consolidated net income less non-controlling interests by the number of shares in issue. The number of shares entitled to receive dividends remained unchanged at 19,404,000 during the fiscal year. There were no outstanding shares as of December 31, 2016, or December 31, 2015, that could have diluted the earnings per share. Earnings per share amounted to € 19.24 (previous year: € 15.74).

The dividends paid in 2014 for the previous fiscal year amounted to € 32 million (previous year: € 32 million). Dividends paid per share in 2016 were € 1.65 (previous year: € 1.65). The Management Board and Supervisory Board are proposing a dividend of € 1.65 per share for fiscal year 2016. The proposed dividend must be ratified by the Annual Shareholders' Meeting on March 28, 2017. This dividend liability is not included in the consolidated financial statements.

12 Other notes to the consolidated statement of income

Material costs

The following material costs are included in the cost of goods sold:

	2016 € '000	2015 € '000
Expenses for raw materials, supplies and goods purchased	2,465,157	2,343,855

In the period under review, expenses related to inventory write-downs recognized in cost of goods sold were € 34,859,000 (previous year: € 30,836,000), and reversals of write-downs from previous periods (increase in net realizable value) were € 9,199,000 (previous year: € 8,737,000).

Payments under operating leases

	2016 € '000	2015 € '000
Payments made under operating leases	102,339	89,686

Payments under operating leases include € 956,000 (previous year: € 925,000). Leasing expenses are predominantly included in cost of goods sold.

Personnel expenditures/employees

The following personnel expenditures are recognized in the statement of income:

Personnel expenses	2016 € '000	2015 € '000
Wages and salaries	1,996,540	1,878,992
Social security payments	304,352	288,002
Welfare and pension expense	87,230	92,924
	2,388,122	2,259,918
Employees by function (average for the year, including temporary employees)		
Production	36,760	35,070
Marketing and sales	12,518	12,309
Research and development	1,902	1,814
Technical and administration	5,669	5,577
	56,849	54,770
of which part-time	(4,042)	(3,309)

Personnel expenditures do not include interest accruing to pension provisions, which is recognized under net interest income.

The average number of employees for the year is prorated based on the date of first consolidation or final consolidation, as appropriate. Employees of joint venture companies are included in the total according to the percentage of interest.

In regard to first-time consolidated companies, an annual average of 274 employees was reported for 2016, compared to 475 for 2015.

13 Total auditor's fee

The following fees were recognized as expenses for services provided worldwide by the auditors of PricewaterhouseCoopers in 2016:

	2016 € '000	2015 € '000
Audit fees	5,214	5,086
of which PricewaterhouseCoopers GmbH, Germany	(1,437)	(1,298)
Other certification services	62	44
of which PricewaterhouseCoopers GmbH, Germany	(23)	(4)
Tax advisory services	1,245	1,056
of which PricewaterhouseCoopers GmbH, Germany	(326)	(271)
Other services	535	595
of which PricewaterhouseCoopers GmbH, Germany	(71)	(22)
	7,056	6,781
of which PricewaterhouseCoopers GmbH, Germany	(1,857)	(1,594)

The audit fees include all fees paid and outstanding to PricewaterhouseCoopers plus reimbursable expenses for the audit of the Group's consolidated financial statements and the audit of the financial statements of B. Braun Melsungen AG and its subsidiaries. Fees for certification services mainly relate to certifications performed as part of acquisitions and divestitures, the examination of internal control systems, particularly IT systems, and expenses related to statutory or judicial requirements. The item tax advisory services mainly relates to fees for advice on completing tax returns, checking tax assessments, support for company audits, or other inquiries conducted by the tax authorities as well as tax advice related to transfer pricing.

NOTES TO THE CONSOLIDATED STATEMENT OF FINANCIAL POSITION

14 Intangible assets

Cost of acquisition or manufacture	Acquired goodwill	Licenses, trademarks, and other similar rights	Internally created intangible assets	Advance payments	Total
	€ '000	€ '000	€ '000	€ '000	€ '000
January 1, 2015	169,517	421,528	85,705	108,870	785,620
Foreign currency translation	252	8,346	9,734	- 12	18,320
Additions to scope of consolidation	13,276	10,338	0	0	23,614
Disposals from scope of consolidation	0	0	0	0	0
Additions	556	16,907	12,961	26,822	57,246
Transfers	28	20,605	0	- 19,814	819
Appreciation	0	0	0	0	0
Disposals	0	- 4,104	0	- 3,954	- 8,058
December 31, 2015/January 1, 2016	183,629	473,620	108,400	111,912	877,561
Foreign currency translation	1,794	6,650	3,369	36	11,849
Additions to scope of consolidation	19,179	8,961	0	0	28,140
Disposals from scope of consolidation	206	- 157	0	0	49
Additions	0	30,192	10,097	24,627	64,916
Transfers	0	32,048	0	- 30,104	1,944
Appreciation	0	0	0	0	0
Disposals	0	- 6,574	0	- 415	- 6,989
December 31, 2016	204,808	544,740	121,866	106,056	977,470
Accumulated amortization 2016	503	335,488	18,144	0	354,135
Accumulated amortization 2015	503	294,420	15,990	0	310,913
Carrying amounts December 31, 2016	204,305	209,252	103,722	106,056	623,335
Carrying amounts December 31, 2015	183,126	179,200	92,410	111,912	566,648
Amortization in the fiscal year	0	38,131	1,571	0	39,702
of which unscheduled	(0)	(97)	(0)	(0)	(97)

Depreciation on intangible assets for the fiscal year was € 39.7 million (previous year: € 39.4 million), recognized in the income statement in functional expenses.

The B. Braun Group capitalized € 10.1 million (previous year: € 13.0 million) in development costs for the fiscal year. All the prerequisites for capitalization were met.

Goodwill is allocated to cash-generating units (CGUs) for the purpose of impairment testing. Each of these cash-generating units represents the Group's investment by the primary reporting segment and the country of operation.

A summary of the distribution of goodwill by cash-generating unit and the assumptions for their impairment testing are listed below:

	Hospital Care	Aesculap	OPM	B. Braun Avitum	Total
	€ '000	€ '000	€ '000	€ '000	€ '000
Dec. 31, 2015					
Carrying amount of goodwill	43,235	9,640	19,153	111,098	183,126
Annual growth rate	1.4%	1.2%	1.0%	1.4%	
Discount rate	7.6%	7.5%	7.2%	7.9%	
Dec. 31, 2016					
Carrying amount of goodwill	44,624	10,528	19,153	130,000	204,305
Annual growth rate	1.9%	1.7%	1.5%	2.0%	
Discount rate	6.7%	6.5%	6.0%	7.0%	

The recoverable amount of a CGU is determined by calculating its value in use. These calculations are based on projected cash flows derived from the three-year forecast approved by management.

Management has determined the budgeted gross margin based on past trends and expectations about future market trends. The weighted average growth rates largely correspond to the predictions from industry reports. The discount rates used are pre-tax rates and reflect the specific risks of the relevant cash-generating units.

If the actual future gross margin had been 10 percent less than the gross margin estimated by management on December 31, 2016, no impairment of goodwill would have occurred. The same holds true if the discount amount that was used to calculate the discounted cash flow had been 10 percent higher than management's estimates.

15 Property, plant, and equipment

Cost of acquisition or manufacture	Land and buildings	Technical plants and machinery	Other plants, operating and office equipment	Advance payments and assets under construction	Total
	€ '000	€ '000	€ '000	€ '000	€ '000
January 1, 2015	1,750,434	2,579,375	864,494	634,051	5,828,354
Foreign currency translation	21,083	15,906	- 401	10,215	46,803
Additions to scope of consolidation	19,035	5,876	2,883	53	27,847
Disposals from scope of consolidation	0	- 2,720	- 1,076	0	- 3,796
Additions	63,790	127,312	74,089	372,482	637,673
Transfers	140,084	220,141	30,724	- 391,768	- 819
Disposals	- 16,253	- 34,022	- 32,781	- 5,059	- 88,115
December 31, 2015/January 1, 2016	1,978,173	2,911,868	937,932	619,974	6,447,947
Foreign currency translation	22,774	33,206	22,527	5,509	84,016
Additions to scope of consolidation	215	162	1,198	0	1,575
Additions	52,380	70,222	78,100	445,214	645,916
Transfers	100,058	225,134	33,422	- 360,558	- 1,944
Disposals	- 4,508	- 45,230	- 33,104	- 694	- 83,536
December 31, 2016	2,149,092	3,195,362	1,040,075	709,445	7,093,974
Accumulated depreciation 2016	615,246	1,806,742	680,164	4,486	3,106,638
Accumulated depreciation 2015	552,198	1,639,494	610,636	3,294	2,805,622
Carrying amounts December 31, 2016	1,533,846	1,388,620	359,911	704,959	3,987,336
Carrying amounts December 31, 2015	1,425,975	1,272,374	327,296	616,680	3,642,325
Depreciation in the fiscal year	61,416	191,363	81,323	3,849	337,951
of which unscheduled	(2,154)	(50)	(487)	(3,849)	(6,540)

Capitalized borrowing costs for the fiscal year were € 6,454,000 (previous year: € 6,291,000). This was based on an interest rate of 2.5 percent (previous year: 2.7 percent).

In the statement of financial position, government grants for investments in the amount of € 925,000 (previous year: € 9,205,000) have been deducted from the carrying amounts of the relevant assets. The current carrying amount of property, plant and equipment acquired with government grants is € 65,928,000 (previous year: € 41,021,000). On the reporting date, no unfulfilled conditions or uncertainties with regards to market success existed, which would have required a modification of recognition in the statement of financial position.

The carrying amount of property, plant and equipment with restricted title is € 15,706,000 (previous year: € 13,523,000).

16 Finance leasing

Intangible assets and property, plant and equipment include the following amounts for which the Group is lessee under a finance lease:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Licenses, trademarks, and similar rights	1,021	1,033
Accumulated amortization	- 371	- 323
Buildings	133,571	133,521
Accumulated depreciation	- 47,196	- 44,634
Technical plants and machinery	7,238	7,410
Accumulated depreciation	- 5,977	- 5,321
Other plants, operating and office equipment	14,953	12,840
Accumulated depreciation	- 10,517	- 9,164
Net carrying amount	92,722	95,362

The minimum lease payments for liabilities under finance leases have the following maturities:

	Dec. 31, 2016			Dec. 31, 2015		
	Nominal value	Discount amount	Net present	Nominal value	Discount amount	Net present
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
Less than one year	13,295	2,140	11,155	10,979	2,481	8,498
Between one and five years	32,065	5,406	26,659	33,007	6,459	26,548
Over five years	19,837	1,187	18,650	29,608	2,142	27,466
	65,197	8,733	56,464	73,594	11,082	62,512

The two largest finance leasing agreements relate to the real estate for the Hospital Care division's LIFE facility (carrying amount: € 22.8 million), and the Aesculap division's benchmark factory (carrying amount: € 15.4 million). These agreements have varying terms and conditions, interest rate adjustment clauses, and purchase options.

17 Financial investments and joint ventures recognized using the equity method of accounting and other financial investments

The B. Braun Group has a 21.6 percent share in Rhön-Klinikum AG, which is headquartered in Bad Neustadt an der Saale. Rhön-Klinikum AG is a publicly traded private operator of hospitals, clinics and medical centers. The B. Braun Group has significant influence over the company based on its percentage of voting rights and representation on its Supervisory Board.

The company's summarized financial information breaks down as follows:

	Assets	Liabilities	Equity	Sales	Profit/ loss	Total earnings	Received dividends
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
2016							
Rhön-Klinikum AG	1,492,595	355,377	1,137,218	1,036,418	82,372	82,181	10,714

Since Rhön-Klinikum AG's net income for 2016 was not available at the B. Braun Group's reporting date, the net income was estimated based on third quarter earnings. The balance sheet values correspond to the values in the third quarter financial statement. The fair value of the investment as of the reporting date was € 370.4 million.

The reconciliation of financial information on the carrying value of the Group's share is as follows:

	Net carrying amount January 1, 2016	Profit/ loss	Change in Equity	Dividend payout	Net carrying amount Dec. 31, 2016	Share in capital 21.6%	Change due to change in equity	Goodwill	Carrying amount Dec. 31, 2016
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
2016									
Rhön-Klinikum AG	1,060,204	64,381	16,299	- 53,550	1,087,334	234,538	66,011	14,231	314,780

The Group's holdings in its other associated companies and joint ventures are as follows:

	2016 € '000	2015 € '000
Other associated companies		
Carrying value of shares	73,885	56,599
Share of profit/loss	1,472	2,960
Share of other income/expense	0	0
Share of net income	1,472	2,960
Joint ventures		
Carrying value of shares	704	1,550
Share of profit/loss	- 122	- 178
Share of other income/expense	0	0
Share of net income	- 122	- 178

As of December 31, 2016, the goodwill of holdings in associated companies totaled € 35.6 million (previous year: € 16.5 million).

Cost of acquisition	Financial investments recognized using the equity method of accounting	Other holdings	Loans to companies in which the Group holds an interest	Securities	Other loans	Total
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
January 1, 2015	331,483	18,406	1,792	723	9,447	361,851
Foreign currency translation	581	0	-89	0	0	492
Additions to scope of consolidation	514	1,275	0	0	34	1,823
Disposals from scope of consolidation	0	-65,567	-1,275	0	0	-66,842
Additions	8,739	77,858	0	4,634	852	92,083
Transfers	-2,375	2,375	0	0	0	0
Appreciation	0	0	0	0	0	0
Disposals	0	-3,850	-26	0	-384	-4,260
Fair value adjustments	0	0	0	-172	0	-172
December 31, 2015/ January 1, 2016	338,942	30,497	402	5,185	9,949	384,975
Foreign currency translation	-3	0	70	0	1	68
Additions to scope of consolidation	0	0	0	0	0	0
Disposals from scope of consolidation	0	-7,744	0	0	0	-7,744
Additions	50,430	15,319	0	0	671	66,420
Transfers	0	0	0	0	0	0
Appreciation	0	0	0	0	0	0
Disposals	0	-1,336	-80	0	-249	-1,665
Fair value adjustments	0	0	0	188	0	188
December 31, 2016	389,369	36,736	392	5,373	10,372	442,242
Accumulated amortization 2016	0	29	0	2,519	20	2,568
Accumulated amortization 2015	0	29	0	0	20	49
Carrying amounts December 31, 2016	389,369	36,707	392	2,854	10,352	439,674
Carrying amounts December 31, 2015	338,942	30,468	402	5,185	9,929	384,926
Amortization in the fiscal year	0	0	0	2,519	0	2,519

18 Trade receivables

Age analysis of trade receivables

A) Non-impaired trade receivables

	Total	Not yet due	Overdue up to 30 days	Overdue 31 to 60 days	Overdue 61 to 90 days	Overdue 91 to 180 days	Overdue more than 180 days
Dec. 31, 2015							
Trade receivables	1,008,396	755,998	81,477	36,356	27,732	48,256	58,577
Dec. 31, 2016							
Trade receivables	1,072,962	818,436	90,584	36,369	24,907	42,034	60,632

A significant proportion of the non-impaired and overdue trade receivables are attributable to receivables from social security providers, government or government-sponsored companies.

b) Trade receivables for which specific impairments have been established

	Total	Not yet due	Overdue up to 30 days	Overdue 31 to 60 days	Overdue 61 to 90 days	Overdue 91 to 180 days	Overdue more than 180 days
Dec. 31, 2015							
Trade receivables	54,204	14,905	1,861	788	2,769	5,180	28,701
Impairment provisions	-27,899	-3,862	-1,004	-345	-1,508	-3,630	-17,550
Carrying amount	26,305	11,043	857	443	1,261	1,550	11,151
Dec. 31, 2016							
Trade receivables	45,347	7,979	1,603	637	540	2,010	32,578
Impairment provisions	-29,230	-3,617	-997	-302	-382	-840	-23,092
Carrying amount	16,117	4,362	606	335	158	1,170	9,486

With regard to trade receivables that are neither impaired nor in arrears, there were no indications as of the reporting date that the debtors in question are not able to meet their payment obligations.

Impairments on trade receivables have changed as follows:

	2016 € '000	2015 € '000
Amount of impairment provisions as of January 1	34,767	28,166
Foreign currency translation	837	- 320
Additions	9,762	14,699
Utilization	- 5,058	- 4,445
Releases	- 2,641	- 3,333
Amount of impairment provisions as of December 31	37,667	34,767
of which specific	(29,230)	(27,899)
of which general	(8,437)	(6,868)

The total amount of additions consists of specific and general provisions for impairment.

The following table shows expenses for the complete derecognition of trade receivables and income from previously derecognized trade receivables:

	2016 € '000	2015 € '000
Expenses for complete derecognition of trade receivables	8,612	7,610
Income from trade receivables previously derecognized	43	63

Fair value of collateral received totaled € 8,035,000 (previous year: € 5,800,000). This collateral consists primarily of payment guarantees.

With regard to trade receivables, there is no concentration with respect to individual customers, currencies, or geographic attributes. The largest receivable from a single customer is equivalent to approx. 1 percent of all trade receivables reported.

As of December 31, 2016, B. Braun Group companies had sold receivables worth € 94.9 million under an asset-backed securities (ABS) program with a maximum volume of € 100 million (previous year: € 92.2 million). The basis for the transaction is the assignment of trade receivables of individual B. Braun companies to a structured entity within the framework of an undisclosed assignment. A structured entity should be consolidated under IFRS 10 if the criteria for control of this company have been met (IFRS 10. B2). The existence of a controlling relationship requires decision-making power and variable returns as well as a link between the two. Since B. Braun does not participate in the variability of the structured entity, this company is not to be consolidated in the consolidated financial statements.

The requirements for a receivables transfer according to IAS 39.15 are met, since the receivables are transferred according to IAS 39.18 a. In previous years, verification in accordance with IAS 39.20 showed that virtually all risks and rewards were neither transferred nor retained. The control of receivables remained with B. Braun, as a further sale of the receivables has been economically detrimental for the structured entity. Therefore, according to IAS 39.30, B. Braun's continuing involvement must be recognized. This included, firstly, the maximum amount that B. Braun could conceivably have to pay back under the senior and third-ranking default guarantee assumed (previous year: € 1,774,000). Secondly, the maximum expected interest payments until payment is received for the carrying amount of the receivables transferred were recognized in the statement of financial position (previous year: € 208,000). The fair value of the guarantee/interest payments to be acquired were estimated at € 113,000 and recorded under other liabilities. In the previous fiscal year, verification in accordance with IAS 39.20 showed that virtually all risks and rewards were neither transferred nor retained. B. Braun's continuing involvement therefore no longer has to be recognized. The maximum amount that B. Braun could conceivably have to pay back under the senior and third-ranking default guarantee assumed is € 1,877,000 as of the reporting date; the maximum expected interest payments until payment is received is € 141,000. The fair value of the guarantee/interest payments to be assumed is € 96,000.

Trade receivables include the following amounts in which the Group is a lessor in a finance lease:

Maturity	Dec. 31, 2016			Dec. 31, 2015		
	Gross investment value	Interest portion included	Present value	Gross investment value	Interest portion included	Present value
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
Less than one year	7,727	1,087	6,640	8,506	975	7,531
Between one and five years	14,370	1,517	12,853	13,312	1,239	12,073
Over five years	167	3	164	397	26	371
Total	22,264	2,607	19,657	22,215	2,240	19,975

The Group leases dialysis machines, infusion pumps, and instrument sets in various operating leases. Total future lease payments under interminable operating leases are as follows:

Maturity	Dec. 31, 2016	Dec. 31, 2015
	Minimum lease payments	Minimum lease payments
	€ '000	€ '000
Less than one year	4,616	2,192
Between one and five years	6,186	2,216
Over five years	3,295	1,665
Total	14,097	6,073

19 Other assets

	Dec. 31, 2016		Dec. 31, 2015	
	Residual term < 1 year € '000	Residual term > 1 year € '000	Residual term < 1 year € '000	Residual term > 1 year € '000
Other tax receivables	68,302	0	63,335	0
Receivables from social security providers	12,007	552	594	558
Receivables from employees	4,712	187	4,480	135
Advance payments	18,326	3	12,520	1
Accruals and deferrals	32,259	3,556	30,639	3,597
	135,606	4,298	111,568	4,291
Receivables from derivative financial instruments	10,095	0	27,533	0
Available-for-sale financial assets	10,442	0	9,456	0
Held-for-trading financial assets	18,683	0	16,976	0
Other receivables and assets	60,379	40,990	72,768	23,853
	99,599	40,990	126,733	23,853
	235,205	45,288	238,301	28,144

Granted loans are mainly reported under other receivables and assets.

With regard to other receivables, as of the reporting date there were no indications that the debtors in question will not be able to meet their payment obligations. No material amounts of receivables were overdue or impaired as of the reporting date.

20 Inventories

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Raw materials and supplies	278,055	252,247
Impairment provisions	- 20,800	- 17,661
Raw materials and supplies – net	257,255	234,586
Work in progress	175,296	179,403
Impairment provisions	- 7,817	- 6,226
Work in progress – net	167,479	173,177
Finished products, merchandise	786,206	716,866
Impairment provisions	- 75,562	- 67,904
Finished products, merchandise – net	710,644	648,962
	1,135,378	1,056,725

As in the previous year, no inventories were pledged as collateral for liabilities.

21 Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits, other short-term highly liquid financial assets with residual maturities of three months or less that are subject to no more than insignificant

fluctuations in value, and bank overdraft facilities. In the statement of financial position, utilized bank overdraft facilities are shown under current financial liabilities as Liabilities to banks.

Changes in cash and cash equivalents are shown in the Consolidated Statement of Cash Flows.

22 Subscribed capital

B. Braun Melsungen's share capital of € 800 million is divided into 19,404,000 no-par-value bearer shares that are fully paid up. Each share without nominal value represents a calculated share of € 41.23 of the subscribed capital.

The Management Board is authorized, with the consent of the Supervisory Board, to increase the subscribed capital by up to € 100 million by issuing new bearer shares for cash on one or more occasions before December 31, 2018.

23 Capital reserves and retained earnings

The capital reserve includes the premium from previous capital increases of B. Braun Melsungen AG.

Retained earnings include past earnings of consolidated companies where these were not distributed and the consolidated net income, net of the share attributable to non-controlling interests. The statutory reserve included in retained earnings amounts to € 29.4 million.

Changes in other provisions	Reserve for cash flow hedges	Fair value of available- for-sale financial assets	Reserve for currency translation differences	Total
	€ '000	€ '000	€ '000	€ '000
January 1, 2015	- 3,693	11	- 83,947	- 87,629
Changes recognized directly in equity (after taxes)				
Changes in fair value of securities	0	- 254	0	- 254
Cash flow hedging instruments	- 140	0	0	- 140
Changes due to currency translation	0	0	- 2,460	- 2,460
Total	- 140	- 254	- 2,460	- 2,854
December 31, 2015/January 1, 2016	- 3,833	- 243	- 86,407	- 90,483
Changes recognized directly in equity (after taxes)				
Changes in fair value of securities	0	155	0	155
Cash flow hedging instruments	- 4,237	0	0	- 4,237
Changes due to currency translation	0	0	64,740	64,740
Total	- 4,237	155	64,740	60,658
December 31, 2016	- 8,070	- 88	- 21,667	- 29,825

Changes in the other equity capital components are shown in the Consolidated Statement of Changes in Equity.

Claims of shareholders to dividend payments are reported as liabilities in the period in which the corresponding resolution is passed.

24 Non-controlling interests

Non-controlling interests relate to third-party interests in the equity of consolidated subsidiaries. They exist in particular at Almo-Erzeugnisse E. Busch GmbH, Bad Arolsen, B. Braun Medical AG, Emmenbrücke, Switzerland, and B. Braun Austria Ges.m.b.H., Maria Enzersdorf, Austria. The summarized financial information of these subsidiaries before inter-company elimination is as follows:

	Assets	Liabilities	Sales
	€ '000	€ '000	€ '000
2015			
Almo-Erzeugnisse E. Busch GmbH, Germany	57,475	34,255	66,763
B. Braun Austria Ges.m.b.H., Austria	73,945	24,481	57,869
B. Braun Medical AG, Switzerland	360,618	127,717	298,191
	492,038	186,453	422,823
2016			
Almo-Erzeugnisse E. Busch GmbH, Germany	56,379	31,840	68,476
B. Braun Austria Ges.m.b.H., Austria	79,654	24,194	60,537
B. Braun Medical AG, Switzerland	365,522	121,942	301,249
	501,555	177,976	430,262

25 Provisions for pensions and similar obligations

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Provisions for pension obligations	1,300,833	1,079,705

Payments of € 42.4 million are expected in fiscal year 2017 (previous year: € 41.5 million). Of this, € 14.1 million is attributable to contributions to external plans (previous year: € 14.1 million) and € 28.3 million (previous year: € 27.4 million) to benefits that will be paid directly by the employer to beneficiaries.

The Group's pension obligations relate to commitments under defined contribution and defined benefit plans.

For defined contribution plans, the Group has no further payment obligations once the contributions have been paid. They are recognized as an operating expense in the amount of the contributions paid. In the previous fiscal year, this amount was € 26.5 million (previous year: € 24.2 million). In addition,

	Profit/ loss	Other earnings (OCI)	Total earnings	Cash flow	Non- controlling interests	attributable to	
						Profit/ loss	Dividends
						€ '000	€ '000
	€ '000	€ '000	€ '000	€ '000	in %	€ '000	€ '000
	2,621	- 1,668	953	1	40	1,048	536
	13,865	- 872	12,993	- 31	40	5,546	3,200
	13,153	- 33,502	- 20,349	44	49	6,445	5,659
	29,639	- 36,042	- 6,403	14		13,039	9,395
	3,901	- 2,910	991	- 1	40	1,560	536
	15,075	- 1,444	13,631	15	40	6,030	3,400
	19,299	- 32,763	- 13,464	- 1,430	49	9,457	5,350
	38,275	- 37,117	1,158	- 1,416		17,047	9,286

the Group makes contributions to statutory basic provision plans for employees in many countries (including Germany). However, since this covers various forms of social security benefits, no precise statement can be made with regard to the part that solely relates to retirement payments. These expenses are shown under social security payments, under Note 12 "Personnel Expenditures/Employees."

Employees' claims under defined benefit plans are based on legal or contractual provisions.

Defined benefit plans based on legal regulations consist primarily of benefit obligations outside Germany at the time of employment termination and are fulfilled in the form of a capital sum. The benefit amount depends mainly on employees' length of service and final salary.

Pension commitments for employees in Germany account for approx. 70 percent of Group pension obligations. These primarily consist of annuity payments made in the event of disability, death, or an employee reaching the retirement age. The main pension plans for employees in Germany who joined the company in 1992 or later are age-dependent defined contribution plans with a modular form. Employees who joined the company before 1992, with a small number of exceptions, received commitments linked to their final salaries.

Retirement benefits in Germany are predominantly financed by pension provisions.

Pension commitments for employees in Switzerland account for approx. 10 percent of Group pension obligations. The benefits consist of annuity payments made in the event of disability, death, or an employee reaching the retirement age. The pension commitments are defined contribution plans with legally prescribed annuity rates based on implicit interest rate guarantees.

Pension commitments for employees in the US account for approx. 10 percent of Group pension obligations. In this case, the pensions have a lump-sum payment option. Payments are made in the event of disability, death, or an employee reaching the retirement age. The pension amount is calculated largely on the basis of the employee's average salary up to 1998. A cash balance scheme applies to any earnings increase after this time.

Retirement benefits in Switzerland and the US are financed by external pension funds, as is customary for both regions. Minimum funding requirements apply in both countries, which could, in rare cases, impact the definition of future financial contributions.

In addition to the longevity risk and the risk of future pension and salary increases, risks faced by the B. Braun Group associated with the benefits payable also include capital market risks, which could impact both income from plan assets and the discount rate.

The liability recognized in the statement of financial position for defined benefit pension plans is the net present value of the defined benefit obligation (DBO) at the reporting date, allowing for future trend assumptions, less the fair value of external plan assets at the reporting date. The defined benefit obligation is calculated using the projected unit credit method. The interest rate used to determine the net present value is usually the yield on prime corporate bonds of similar maturity.

The amount of pension provisions in the statement of financial position is derived as follows:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Present value of pension obligations	1,609,146	1,373,148
Fair value of external plan assets	- 308,313	- 293,443
Excess cover/shortfall	1,300,833	1,079,705
Effect of asset ceiling	0	0
Pension provision (net)	1,300,833	1,079,705
of which assets	(763)	(799)
of which liabilities	(1,301,596)	(1,080,504)

Pension expenses included in the statement of income consist of the following:

	2016 € '000	2015 € '000
Current service costs	51,339	54,895
Plan changes/past service costs	- 3,990	- 605
(Profit)/losses from plan settlements/lapsing	- 1,312	- 2,153
Service costs	46,037	52,137
Interest expense on pension obligations	36,594	33,883
Interest income from external plan assets	- 7,165	- 7,271
Interest income from reimbursement claims	0	0
Interest on asset ceiling	0	0
Net interest expense on pension obligations	29,429	26,612
Administrative expenses and taxes	1,061	783
Pension expense on defined benefit plans	76,527	79,532
of which operating profit	(47,098)	(52,920)
of which financial income	(29,429)	(26,612)
Pension expense on defined contribution plans	26,503	24,202
Pension expense	103,030	103,734

Pension obligations and external plan assets are reconciled as follows:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Present value of the obligation at the beginning of the year	1,373,148	1,366,903
Current service costs	51,339	54,895
Plan changes (past service costs)	- 3,990	- 605
Effects of plan settlements/lapsing	- 1,312	- 2,153
Interest expense on pension obligations	36,594	33,883
Benefits paid excluding administrative costs	- 42,020	- 38,234
Settlement payments	- 1,760	- 3,291
Employee contributions	4,489	4,408
Effects of changes in financial assumptions	199,329	- 83,976
Effects of changes in demographic assumptions	- 3,807	- 1,315
Effects of experience adjustments	- 3,252	10,065
Effects of transfers	- 264	1,765
Effects of changes in the scope of consolidation	0	0
Effects of foreign currency translation	652	30,803
Present value of the obligation at end of year	1,609,146	1,373,148

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Fair value of plan assets at the beginning of the year	293,443	268,429
Interest income from external plan assets	7,165	7,271
Revaluation of external plan assets	7,813	- 6,522
Employer contributions	13,962	11,671
Employee contributions	4,489	4,408
Benefits paid and fund capital payments made	- 15,710	- 12,976
Settlement payments	- 1,760	- 3,287
Effects of changes in scope of consolidation and transfers	- 349	1,738
Effects of foreign currency translation	- 740	22,711
Fair value of plan assets at the end of the year	308,313	293,443

The plan assets consist of the following:

	Dec. 31, 2016 in %	Dec. 31, 2015 in %
Equities and similar securities	21	22
Bonds and other fixed-income securities	14	13
Real estate	0	0
Insurance contracts	56	55
Liquid assets	1	1
Derivatives	0	0
Investment funds	8	9
Other assets	0	0
	100	100

The plan assets for which traded market prices exist are as follows:

	Dec. 31, 2016 in %	Dec. 31, 2015 in %
Equities and similar securities	21	22
Bonds and other fixed-income securities	14	13
Real estate	0	0
Insurance contracts	0	0
Liquid assets	1	1
Derivatives	0	0
Investment funds	8	9
Other assets	0	0
	44	45

Plan assets are not invested in the Group's own financial instruments.

87 percent of the equities and similar securities are attributable to plan assets in the United States. A pension committee oversees plan assets in the United States and ensures adequate investment diversification.

In fiscal years 2016 and 2015, the pension provisions changed as follows:

	2016 € '000	2015 € '000
Pension provisions (net) January 1	1,079,705	1,098,474
Transfers	85	27
Payments	- 41,337	- 37,720
Pension expense	76,527	79,532
Revaluations recognized in equity (OCI)	184,460	- 68,700
of which effects from changes to financial assumptions of the pension obligation	(199,329)	(- 83,976)
of which effects from changes to demographic assumptions of the pension obligation	(- 3,807)	(- 1,315)
of which effects from experiential adjustments of the pension obligation	(- 3,252)	(10,065)
of which revaluation of external plan assets	(- 7,813)	(6,522)
of which other effects	(3)	(4)
Effects of changes in the scope of consolidation	0	0
Effects of foreign currency translation	1,393	8,092
Pension provisions (net) December 31	1,300,833	1,079,705

The calculation of pension obligations was based on the following assumptions:

	Dec. 31, 2016 in %	Dec. 31, 2015 in %
Discount rate	2.0	2.7
Future salary increases	2.8	2.8
Future pension increases	1.5	1.5

Pension expense was calculated using the following assumptions:

	2016 in %	2015 in %
Discount rate for calculating interest expense	2.7	2.5
Discount rate for calculating current service costs	3.0	2.6
Future salary increases	2.8	2.9
Future pension increases	1.5	1.5

The percentages shown are weighted average assumptions. For the eurozone, a uniform discount rate of 2.0 percent (previous year: 2.8 percent) was applied to determine the pension obligations.

The Heubeck Mortality Tables 2005 G served as the basis for measuring German-defined benefit (pension) obligations, as in the previous year.

The results of the sensitivity analysis were determined using the previous year's methods, changing one assumption at a time and leaving the other assumptions unchanged. No account was taken of any possible correlations between the individual assumptions.

The results of the sensitivity analysis were as follows:

Obligation-increasing effect	2016 in %	2015 in %
Discount rate reduced by 25 basis points	4	4
Future salary increases increased by 25 basis points	1	1
Future pension increases increased by 25 basis points	2	2
Life expectancy increased by 1 year	3*	3*

* Effect within Germany

Obligation-reducing sensitivities have a comparable effect.

The weighted duration of the obligation is 19 years (previous year: 18 years).

26 Other provisions

The major provisions categories changed as follows:

Other non-current provisions	Personnel expenditures € '000	Uncertain liabilities € '000	Other € '000	Total € '000
January 1, 2015	64,497	6,918	8,243	79,659
Foreign currency translation	2,055	- 842	- 162	1,052
Changes in scope of consolidation	0	0	0	0
Accrued interest	0	0	0	0
Transfers	0	0	0	0
Utilization	- 3,199	- 1,529	- 466	- 5,194
Reversals	- 385	- 14	0	- 399
Additions	18,770	1,976	2,373	23,118
December 31, 2015/January 1, 2016	81,738	6,509	9,988	98,235
Foreign currency translation	622	232	186	1,039
Translation scope of consolidation	0	0	0	0
Accrued interest	0	52	0	52
Transfers	0	0	0	0
Utilization	- 5,764	- 877	- 2,807	- 9,448
Reversals	- 3,204	- 332	- 308	- 3,844
Additions	23,520	1,295	1,844	26,660
December 31, 2016	96,911	6,879	8,904	112,694

Other current provisions	Personnel expenditures	Warranties	Uncertain liabilities	Other	Total
	€ '000	€ '000	€ '000	€ '000	€ '000
January 1, 2015	1,965	8,732	7,460	21,473	39,630
Foreign currency translation	86	240	382	- 190	518
Transfers	0	0	0	0	0
Translation scope of consolidation	842	0	0	2,893	3,735
Utilization	- 1,603	- 6,126	- 1,656	- 10,812	- 20,198
Reversals	- 568	- 1,378	- 464	- 5,387	- 7,797
Additions	2,411	8,310	6,895	16,128	33,744
December 31, 2015/January 1, 2016	3,133	9,778	12,617	24,105	49,632
Foreign currency translation	11	- 25	201	- 85	103
Transfers	0	0	0	0	0
Translation scope of consolidation	0	0	0	0	0
Utilization	- 2,090	- 4,690	- 8,290	- 13,167	- 28,238
Reversals	- 422	- 1,277	- 604	- 2,778	- 5,081
Additions	3,067	6,982	5,383	16,821	32,254
December 31, 2016	3,699	10,768	9,307	24,896	48,670

Non-current provisions for personnel expenditures primarily consist of provisions for partial retirement plans and anniversary payments.

Other provisions mainly consist of provisions for other obligations in the area of personnel and social services, guarantees, possible losses from contracts, legal and consulting fees, and a number of identifiable individual risks. The additional other provisions refer predominantly to outstanding invoices, bonuses, actuarial provisions, and provisions for not yet settled insurance claims of REVIUM Rückversicherung AG, Melsungen.

The release of provisions affecting net income is primarily attributable to the release of provisions for personnel expenditures in Germany (€ 2,840,000) and for warranties in the United States (€ 1,113,000).

The majority of non-current provisions will result in payments due within five years.

27 Financial liabilities

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Non-current liabilities		
Profit participation rights	98,116	90,897
Liabilities to banks	1,027,728	977,593
Liabilities under finance leases	24,476	29,990
Liabilities under finance leases with affiliated companies	20,833	24,003
Liabilities under borrowings from non-banks	15,030	32,508
Other financial liabilities	0	0
	1,186,183	1,154,991
Current liabilities		
Profit participation rights	13,319	11,238
Liabilities to banks	587,531	604,385
Liabilities under finance leases	7,985	5,457
Liabilities under finance leases with affiliated companies	3,170	3,062
Liabilities under borrowings from non-banks	151,836	103,920
Liabilities under bills of exchange	14,746	20,375
Other financial liabilities	27,358	19,937
	805,945	768,374
Total financial liabilities	1,992,128	1,923,365

Other financial liabilities include € 21,178,000 in advance payments received for orders (previous year: € 13,427,000).

Term structure of financial liabilities:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Due within one year	805,945	768,374
Due in one to five years	877,266	693,201
Due in over five years	308,917	461,790
	1,992,128	1,923,365

Under the B. Braun Incentive Plan, B. Braun Melsungen AG offers a series of profit participation rights, which may be acquired by eligible managers on a voluntary basis. With the issuance of profit participation rights, the company grants employees profit-sharing rights in the form of participation in the profit and losses of B. Braun Melsungen AG in return for their investment of capital.

Each profit participation right has a ten-year term. Interest on the rights is linked to the dividends paid to shareholders in B. Braun Melsungen AG, and the repayment amount is linked to the Group's equity.

As an incentive for the investment made by employees, the company offers an entitlement bonus of 25 percent in the form of additionally assigned participation rights. The entitlement bonus is paid to employees two years after their investment. The additional profit participation rights are recognized as expenses in the corresponding periods.

As of December 31, 2016, a total of 689,615 rights had been issued. The years of issue are as follows:

Year of issue	Number
2007	66,107
2008	79,149
2009	69,123
2010	80,217
2011	69,202
2012	54,071
2013	69,276
2014	62,481
2015	64,761
2016	75,228
	689,615

The B. Braun Melsungen AG, together with several subsidiaries and 12 banks, concluded a new syndicated loan agreement for € 400 million in March 2012. The loan may be used by the borrowers as revolving credit in EUR, or alternatively in partial sums in USD and GBP, and bears a variable interest rate based on Euribor and Libor for the currency in question. In addition, the agreement allows for an adjustment to the interest margin depending on the B. Braun Group's net financial debt (leverage ratio). In May 2014, the parties agreed to extend the term of the original credit agreement that was supposed to end on March 23, 2017, to May 21, 2019. In addition, B. Braun has been granted the right to extend the contract by one year on two separate occasions upon consent of the banks. In 2016, a second extension (until May 2021) and an increase in the committed credit volume to € 520 million were granted. Under the terms of the syndicated loan agreement, B. Braun is required to comply with certain financial ratios, including, in particular, a minimum equity ratio, which is calculated by taking the entity's total assets and dividing them by its total equity, and maximum leverage ratio, in other words, the net financial debt to EBITDA ratio. Both of these ratios will be calculated on the basis of consolidated figures for the B. Braun Group, subject to adjustments as agreed under the syndicated loan. Under the agreement, the equity ratio must not fall below 25 percent and the leverage ratio must not exceed 3.25. During the fiscal year and as of the reporting date, both ratios were fully complied with.

In 2016, B. Braun Melsungen AG secured a bilateral bank loan of € 100 million at a fixed interest rate that will be due in 2020. In addition, Group companies in Asia have secured long-term, bilateral loan agreements equivalent to approx. € 120 million with terms of up to 10 years. These borrowed funds were used to refinance expired loans and finance the capital requirements of each Group company.

As of December 31, 2016, the Group had unused credit lines in different currencies totaling € 1,118.7 million (previous year: € 1,011.7 million).

Interest rates on euro loans were up to 5.40 percent per annum for non-current loans, depending on the length of the interest rate lock-in period.

The carrying amounts of the interest-bearing liabilities are as follows for the currencies below:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
EUR	1,470,994	1,445,151
USD	184,251	214,735
Other	336,883	263,479
	1,992,128	1,923,365

Liabilities from finance leasing are recognized at the net present value of the leasing payments. These are fully secured by property liens on leased property. Of the other liabilities, € 19,904,000 (previous year: € 18,040,000) are secured by property liens. Liabilities under borrowings from non-banks include loans from B. Braun Melsungen AG shareholders in the amount of € 75,638,000 (previous year: € 65,416,000). Borrowings from non-banks are unsecured.

The carrying amount of financial assets used as collateral for liabilities or contingent liabilities was € 34,000 (previous year: € 33,000). The collateral provided was assigned receivables. The following table shows the contractually agreed upon (undiscounted) interest and repayments on financial liabilities, other financial liabilities, and derivative financial instruments with negative fair value:

	Carrying amount € '000	Cash outflows within one year	
		Interest € '000	Repayments € '000
Dec. 31, 2015			
Profit participation rights	102,135	152	11,238
Liabilities to banks	1,581,978	24,504	604,385
Liabilities under finance leases	35,447	1,626	5,457
Liabilities under finance leases with affiliated companies	27,065	854	3,062
Liabilities under borrowings from non-banks	136,428	958	103,920
Liabilities from ABS transactions and other financial liabilities	60,086	0	60,086
Financial liabilities trade accounts payable	348,615	0	344,113
Liabilities from derivative financial instruments	18,523	0	358,252
Dec. 31, 2016			
Profit participation rights	111,435	152	13,319
Liabilities to banks	1,615,259	25,501	587,531
Liabilities under finance leases	32,461	1,395	7,985
Liabilities under finance leases with affiliated companies	24,003	746	3,170
Liabilities under borrowings from non-banks	166,866	889	151,836
Liabilities from ABS transactions and other financial liabilities	53,891	0	53,891
Trade accounts payable	442,879	0	438,240
Liabilities from derivative financial instruments	34,233	-2	410,970

All instruments held as of December 31, 2016 and for which payments had already been contractually agreed upon are included. Amounts in foreign currency were each translated at the closing rate on the

	Cash outflows within one to two years		Cash outflows within two to five years		Cash outflows within five to ten years		Cash outflows after ten years	
	Interest	Repayments	Interest	Repayments	Interest	Repayments	Interest	Repayments
	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000	€ '000
	135	12,173	293	35,514	185	43,210	0	0
	21,504	182,344	34,918	416,896	14,535	378,353	0	0
	1,338	7,014	2,821	9,241	1,489	13,176	42	559
	746	3,170	1,560	9,802	613	11,031	0	0
	770	18,304	494	11,715	0	2,420	0	69
	0	0	0	0	0	0	0	0
	0	81	0	2,350	0	2,071	0	0
	-1	1,597	1	685	0	0	0	-342,011
	134	15,984	290	34,248	198	47,884	0	0
	24,405	147,623	39,133	653,546	12,172	226,559	0	0
	1,135	4,106	2,407	9,563	868	10,429	12	378
	634	3,282	1,232	9,707	307	7,844	0	0
	117	1,934	26	10,261	0	2,835	0	0
	0	0	0	0	0	0	0	0
	0	1,599	0	1,464	0	1,576	0	0
	-2	4,352	-2	602	0	0	0	-381,691

reporting date. The variable interest payments arising from the financial instruments were calculated using the last interest rates fixed before December 31, 2016. Financial liabilities that can be repaid at any time are always assigned to the earliest possible period.

28 Additional disclosures on financial instruments

Carrying amount and fair value by measurement category

	Assessment category under IAS 39	Carrying amount Dec. 31, 2016 € '000	Fair value Dec. 31, 2016 € '000	Carrying amount Dec. 31, 2015 € '000	Fair value Dec. 31, 2015 € '000
Assets					
Trade receivables	LaR	1,089,079	–	1,034,701	–
Other receivables	LaR	128,429	–	116,316	–
Available-for-sale financial assets	AfS	13,296	13,296	14,641	14,641
Other holdings	AfS	36,707	–*	30,468	–*
Financial assets held for trading	FAHfT	18,683	18,683	16,976	16,976
Derivatives not in a hedge	FAHfT	7,136	7,136	20,283	20,283
Derivatives in a hedge	n. a.	2,959	2,959	7,250	7,250
Cash and cash equivalents	LaR	90,456	–	62,958	–
Liabilities					
Profit participation rights	FLAC	111,435	–**	102,135	–**
Liabilities to banks	FLAC	1,615,259	1,645,604	1,581,978	1,609,099
Liabilities under finance leases	n. a.	56,464	56,956	62,512	63,695
Liabilities under borrowings from non-banks	FLAC	166,866	167,321	136,428	137,521
Other financial liabilities	FLAC	35,924	–	33,802	–
Trade accounts payable	FLAC	442,879	–	348,615	–
Other liabilities	FLAC	285,719	–	258,600	–
Purchase price liabilities from business combinations	FLHfT	1,379	1,379	28,614	28,614
Derivatives not in a hedge	FLHfT	19,538	19,538	6,794	6,794
Derivatives in a hedge	n. a.	14,695	14,695	11,729	11,729
Summary by IAS 39 measurement category:					
Loans and receivables	LaR	1,307,964	1,311,157	1,213,975	1,214,918
Available-for-sale financial assets	AfS	50,003	50,003	45,109	45,109
Financial assets held for trading	FAHfT	25,819	25,819	37,259	37,259
Financial liabilities measured at amortized cost	FLAC	2,658,082	2,688,882	2,461,558	2,489,772
Financial liabilities measured at fair value	FLHfT	20,917	20,917	35,408	35,408

LaR Loans and Receivables | **HtM** Held-to-Maturity Financial Assets | **AfS** Available-for-Sale Financial Assets | **FAHfT** Financial Assets Held-for-Trading
FLAC Financial Liabilities measured at Amortized Cost | **FLHfT** Financial Liabilities Held-for-Trading

* The remaining holdings consist of shares in partnerships and corporations for which no active market exists. Since future cash flow cannot be reliably determined, the fair value of these instruments also cannot be reliably measured.

** Interest on the rights is linked to the dividends paid to shareholders in B. Braun Melsungen AG, and the repayment amount is linked to the Group's equity. A fair value for this instrument cannot be reliably measured.

Net gains or losses by measurement category are as follows:

Net gains or losses from	2016 € '000	2015 € '000
- available-for-sale financial assets	-2,589	- 18
- financial assets and liabilities held for trading	-34,259	-7,882
	-36,848	-7,900

Available-for-sale financial assets comprise:

Equities and similar securities	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Listed securities	13,296	14,641
of which non-current	(2,854)	(5,185)

These are reported under other financial investments and other financial assets. No available-for-sale financial assets were impaired in 2016 or 2015. There is no plan to dispose of these assets or the remaining holdings.

Other assets include other receivables and other financial assets in the amount of € 119,698,000 (previous year: € 109,142,000) and other loans in the amount of € 10,744,000 (previous year: € 10,331,000).

The maximum credit risk for each measurement category of financial assets corresponds to its carrying amount. Trade receivables are partly secured with reservation of title, which reduces the maximum default risk in this assessment category by € 29,807,000 (previous year: € 36,946,000).

Cash and cash equivalents, trade receivables, and other receivables have predominantly short residual terms, thus their carrying amounts are close to fair value as of the reporting date.

Trade accounts payable and other financial liabilities and debt regularly have short residual terms; the values reported on the statement of financial position are close to fair value.

The fair values of liabilities to banks and other lenders, promissory notes, finance leases, and other financial liabilities are calculated as the net present value of the payments associated with the liabilities, based on the relevant yield curve in each case. In determining the fair value, the credit risk has been taken into account.

The table below shows financial instruments where subsequent measurement and accounting is at fair value. These are categorized into levels 1 to 3, depending on the extent to which fair value can be measured:

- Level 1 – Measurement at fair value based on (unadjusted) quoted prices on active markets for identical financial assets or liabilities.
- Level 2 – Measurement at fair value based on parameters, which are not quoted prices for assets or liabilities as in level 1, but which are either directly derived from them (i. e., as prices) or indirectly derived from them (i. e., derived from prices).
- Level 3 – Measurement at fair value using models that include parameters not based on observable market data to value assets and liabilities.

	Level 1 € '000	Level 2 € '000	Level 3 € '000	Total € '000
December 31, 2015				
Financial assets of category "At fair value through profit and loss"				
Derivative financial assets not in a hedge	0	20,283	0	20,283
Derivative financial assets in a hedge	0	7,250	0	7,250
Financial assets held for trading	16,976	0	0	16,976
Financial assets of category "Available-for-sale"				
Financial assets	14,641	0	0	14,641
Financial liabilities of category "At fair value through profit and loss"				
Purchase price liabilities from business combinations	0	0	-28,614	-28,614
Derivative financial assets not in a hedge	0	-6,794	0	-6,794
Derivative financial assets in a hedge	0	-11,729	0	-11,729
	31,617	9,010	-28,614	12,013
December 31, 2016				
Financial assets of category "At fair value through profit and loss"				
Derivative financial assets not in a hedge	0	7,136	0	7,136
Derivative financial assets in a hedge	0	2,959	0	2,959
Financial assets held for trading	18,683	0	0	18,683
Financial assets of category "Available-for-sale"				
Financial assets	13,296	0	0	13,296
Financial liabilities of category "At fair value through profit and loss"				
Purchase price liabilities from business combinations	0	0	-1,379	-1,379
Derivative financial assets not in a hedge	0	-19,538	0	-19,538
Derivative financial assets in a hedge	0	-14,695	0	-14,695
	31,979	-24,138	-1,379	6,462

Purchase price liabilities from business combinations categorized as Level 3 are conditional purchase price liabilities recorded at net present value, the final amount of which is partially performance-dependent based on the sale of acquired companies in the years following acquisition. If sales turn out to be 10 percent higher (lower) than was assumed when the liability was determined, then the liability would increase (decrease) by € 138,000.

The € 27,235,000 decrease in liabilities over the previous year is attributable to the repayment of purchase price liabilities (–€ 21,986,000) and the revaluation of measurement parameters (–€ 5,249,000).

The table below shows financial instruments that are subsequently measured at fair value, but recognized at amortized cost.

	Level 1 € '000	Level 2 € '000	Level 3 € '000	Total € '000
December 31, 2015				
Financial liabilities of category "Measured at amortized cost"				
Liabilities to banks	0	1,609,099	0	1,609,099
Liabilities under finance leases	0	63,695	0	63,695
Liabilities under borrowings from non-banks	0	137,521	0	137,521
	0	1,810,315	0	1,810,315
December 31, 2016				
Financial liabilities of category "Measured at amortized cost"				
Liabilities to banks	0	1,645,604	0	1,645,604
Liabilities under finance leases	0	56,956	0	56,956
Liabilities under borrowings from non-banks	0	167,321	0	167,321
	0	1,869,881	0	1,869,881

The following financial assets and liabilities are subject to offsetting arrangements:

	Gross carrying amount € '000	Offset amount € '000	Net carrying amount € '000	Corresponding amounts that were not offset		Net amount € '000
				Financial instruments € '000	Financial collateral held € '000	
December 31, 2015						
Loans and receivables (LaR)	1,213,975	0	1,213,975	- 7,323	0	1,206,652
Financial assets held for trading (FAHfT)	37,259	0	37,259	- 22,303	0	14,956
Financial liabilities measured at amortized cost (FLAC)	2,461,558	0	2,461,558	- 20,593	16	2,440,981
Financial liabilities held for trading (FLHfT)	35,408	0	35,408	- 9,033	0	26,375
December 31, 2016						
Loans and receivables (LaR)	1,307,964	0	1,307,964	- 11,563	0	1,296,401
Financial assets held for trading (FAHfT)	25,819	0	25,819	- 6,688	0	19,131
Financial liabilities measured at amortized cost (FLAC)	2,658,082	0	2,658,082	- 7,519	0	2,650,563
Financial liabilities held for trading (FLHfT)	20,917	0	20,917	- 10,732	0	10,185

Offsetting of amounts that were not offset is permitted in the event of bankruptcy or default of one of the contractual parties.

29 Trade accounts payable and other liabilities

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Non-current liabilities		
Trade accounts payable	4,639	4,502
Liabilities to social security providers	2,931	1,839
Liabilities to employees, management, and shareholders	23,438	18,750
Accruals and deferrals	80	0
	26,449	20,589
Other liabilities	11,346	19,253
Subtotal other liabilities	37,795	39,842
of which financial liabilities	(11,346)	(19,251)
Current liabilities		
Trade accounts payable	438,240	344,113
Liabilities to social security providers	32,477	32,235
Liabilities to employees, management, and shareholders	277,226	268,904
Accruals and deferrals	12,310	16,109
Other tax liabilities	78,671	72,284
	400,684	389,532
Liabilities from derivative financial instruments	34,233	18,523
Other liabilities	282,000	273,128
	316,233	291,651
Subtotal other liabilities	716,917	681,183
of which other financial liabilities	(309,985)	(286,486)
Total liabilities	1,197,591	1,069,640

The Group has designated several payer interest rate swaps ("static pay – variable receipts") as cash flow hedges in order to hedge the variable interest payments on a nominal credit volume of € 125,000,000 (previous year: € 125,000,000). Changes in the cash flows of the underlying transaction resulting from changes in the reference interest rate are compensated for by the changes in the cash flows of the

interest rate swap. The hedging measures are designed to hedge the cash flow from bank liabilities against an increase in the reference interest rate. Credit risks are not covered through the hedge. The related cash flows are likely to occur through fiscal year 2019. The effectiveness of hedges was measured prospectively and retrospectively using the dollar offset method. The hedges were effective. The effective portion of changes in the fair value of the designated interest rate swap is recognized in equity and amounts to a total of –€ 717,000 (previous year: –€ 847,000). The ineffective portion of changes in value is recognized directly in the statement of income under net financial income and is € 0 (previous year: € 0). Amounts accrued under equity are transferred to the statement of income as income or expense in the period in which the hedged underlying transaction is recognized in the statement of income.

From hedges that were terminated or became ineffective in the fiscal year, losses that were recognized in the capital equity on an accumulative basis remained in the capital equity at the time of terminating this hedge, and they are recognized on entry of the originally hedged transaction in the statement of income. In 2016, this resulted in an expense of € 555,000 (previous year: € 555,000), which was transferred from equity to the statement of income.

Other liabilities mainly include remaining payments related to company acquisitions, liabilities from ABS transactions, bonus obligations, and liabilities related to outstanding invoices.

30 Contingent liabilities

Liabilities result exclusively from obligations to third parties and consist of:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Uncertain liabilities	22,162	39,364
Guarantees	12,820	21,225
Warranties	137	1,973
Contractual performance guarantees	39,257	46,496
	74,376	109,058

All cases relate to potential future obligations, which may arise upon the occurrence of corresponding events and are entirely uncertain as of the reporting date.

31 Other financial liabilities

The Group leases numerous office buildings and warehouses under non-terminable operating lease agreements. These agreements have varying terms and conditions, escalation clauses, and renewal options.

Future minimum lease payments expected in connection with non-terminable sub-leases on the reporting date amount to € 9,541,000 (previous year: € 12,080,000).

The Group also leases manufacturing facilities and machinery under terminable operating lease agreements.

The minimum payments of non-discounted future lease payments under operating lease are due as follows:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Obligations under rental and leasing agreements		
Due within one year	79,681	68,125
Due within one to five years	147,037	110,531
Due in over five years	84,525	63,778
	311,243	242,434
Obligations from the acquisition of intangible assets	349	18
Obligations from the acquisition of property, plant, and equipment	198,892	171,172
Total	510,484	413,624

Some Group companies enter into sale and leaseback agreements with B. Braun Holding GmbH & Co. KG as part of their operating activities. These agreements are intended for sales financing, not to realize profits earlier.

The portion of total obligations under rental and lease agreements accounted for by obligations under sale and leaseback agreements is provided in the table below:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Obligations under sale and leaseback agreements		
Due within one year	10,390	8,325
Due within one to five years	19,216	13,586
Due in over five years	0	0
	29,606	21,911

During the normal course of business, B. Braun is subject to potential obligations stemming from lawsuits and enforced claims. Estimates of possible future liabilities of this kind are uncertain. No material negative consequences for the economic or financial situation of the B. Braun Group are anticipated.

32 Financial risk management

Financial risk factors

The Group's activities expose it to a variety of financial risks. These include currency, interest rate, credit and liquidity risks. The B. Braun Group's policy strives to minimize these risks via systematic risk management, which involves the use of derivative financial instruments.

Risk management is performed centrally by Group Treasury in accordance with policies approved by the Management Board. Group Treasury identifies, measures and hedges financial risks in close cooperation with the Group's operating units. The Management Board provides written principles for Group-wide risk

management together with written policies covering specific areas such as foreign exchange, interest rate and credit risk and the use of derivative and non-derivative financial instruments.

a) Market risk

Foreign exchange risk

The Group operates internationally and is therefore exposed to currency risk arising from fluctuations in the exchange rates between various foreign currencies, primarily the US dollar. Risks arise when future transactions, assets and liabilities recognized in the statement of financial position are denominated in a currency that is not the functional currency of the company. To hedge such risks, the Group uses forward foreign exchange contracts.

The Group's risk management policy is to hedge the assets or liabilities recognized in the statement of financial position and to hedge up to 60 percent of the net cash flow expected over the next fiscal year on a continuous basis in key currencies. The Group therefore performs a scenario analysis to ascertain the impact of changes in exchange rate on the Group's earnings and shareholders' equity (before taxes in each case). This analysis takes into account balance sheet items (particularly accounts receivable and payable from operations, as well as loans and borrowings) as well as foreign exchange transactions executed in order to hedge balance sheet items and future cash flow denominated in foreign currencies (cash flow hedges).

If the exchange rate of the US dollar compared to other currencies on December 31, 2016, had been 10 percent stronger (weaker), profit before taxes – with all other variables remaining constant – would have been € 0.5 million (previous year: € 4.8 million) lower (higher). The remaining components of equity would have been approx. € 6.5 million (previous year: € 12.3 million) lower (higher). If the euro rises in value by 10 percent against all other currencies (euro 10 percent weaker), the changes in the value of the cash flow hedges would have the effect of increasing (decreasing) shareholders' equity by about € 19.7 million (previous year: € 19.3 million).

Interest rate risk

As the Group has no significant interest-bearing assets, changes in market interest rates affect its income and operating cash flow primarily via their impact on its interest-bearing liabilities. The liabilities with variable interest rates expose the Group to cash flow interest rate risk. Fair value interest rate risk arises from fixed-interest liabilities. Group policy is to maintain approx. 50 percent of its borrowings in fixed-rate instruments.

The Group also hedges its cash flow interest rate risk using interest rate swaps. Under these interest rate swaps, the Group agrees with other parties to exchange a fixed interest rate for a floating reference rate at specified intervals based on the agreed nominal volume in each case. Interest rate swaps of this nature have the economic effect of converting variable-rate into fixed-rate loans.

If market interest rates had been 100 basis points higher as of December 31, 2016, profit before taxes – with all other variables remaining constant – would have been approx. € 4.5 million lower for the full year (previous year: € 5.2 million). If market interest rates had been 100 basis points lower as of December 31, 2016, profit before taxes – with all other variables remaining constant – would have been approx. € 4.5 million higher for the full year (previous year: € 2.6 million). This would have been mainly attributable to higher or lower interest expense for variable-rate interest-bearing financial liabilities. The other components of equity would have changed only slightly.

b) Credit risk

The Group has no significant concentrations of credit risk related to trade receivables. It has organizational guidelines that ensure that products are sold only to customers with a good payment history. Contracts on derivative financial instruments and financial transactions are solely concluded with financial institutions with a good credit rating and contain, as a rule, a provision that allows mutually offsetting positive and negative fair market values in the event of the insolvency of a party.

c) Liquidity risk

Prudent liquidity risk management includes maintaining sufficient reserves of cash, as well as ensuring the availability of funding through an adequate amount of committed credit facilities. Due to the dynamic nature of the environment in which the Group operates, Group Treasury aims to maintain the necessary flexibility in funding by ensuring that sufficient unused credit lines are available.

Capital risk management

The Group's capital management seeks to ensure continuation as a thriving, independent, family-run company, in order to guarantee that shareholders continue to receive dividends and other interested parties receive the amounts owed them, as well as maintaining an optimal equity structure to reduce the cost of capital.

The goal of significantly exceeding an equity ratio of at least 25 percent, as per the terms of the syndicated loan, was met in fiscal year 2016, as well.

Derivative financial instruments

The fair value of derivative financial instruments is calculated using directly observable market input factors. The fair value of interest rate swaps is calculated from the net present value of estimated future cash flows using the relevant yield curve on the reporting date. The fair value of forward foreign exchange contracts is calculated based on forward exchange rates on the reporting date. The company's own credit risk or counterparty credit risk is not included in this calculation due to a lack of materiality.

Changes in the fair value of derivative financial instruments that represent economically effective hedges under the Group strategy are recognized through profit and loss, unless they are used in hedge accounting. When applying hedge accounting for cash flow hedges, the fair market value changes from the effective portion are recognized in equity. The fair value changes in hedging instruments more or less match the fair value changes in the hedged underlying transactions.

	Nominal volume		Nominal volume residual term > 1 year		Fair value	
	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Forward foreign exchange contracts	959,793	1,028,930	46,282	57,191	-21,697	10,793
Currency options	125,000	125,000	100,000	125,000	-2,782	-3,438
Embedded derivatives	6,500	7,636	0	0	106	339
	1,091,293	1,161,566	146,282	182,191	-24,373	7,694

Depending on the fair value on the reporting date, derivative financial instruments are included under other assets (if fair value is positive) or other liabilities (if fair value is negative).

See Note 29 regarding cash flow hedges recognized under other liabilities.

The Group designates forward foreign exchange contracts to hedge future foreign currency inflows and outflows from the operating business of the B. Braun Group that are not denominated in the functional currency and are expected to arise with high probability. In addition, the Group allocates currency hedges to certain plant construction projects and intercompany loans that are not contracted in the functional currency of each Group company. The purpose of the hedges is to reduce the profit or loss volatility resulting from foreign exchange receipts and payments (and their measurement) with respect to foreign exchange risk. The effectiveness of hedges is measured prospectively using the critical terms match method and retroactively using the dollar offset method.

As of December 31, 2016, the Group had designated forward foreign exchange contracts with a net fair value of –€ 9,534,000 (previous year: –€ 1,560,000) as cash flow hedges. All hedges were effective within the range specified under IAS 39.

Gains of € 9,891,000 (previous year: € 30,165,000) and losses of € 26,292,000 (previous year: € 46,722,000) from changes in the fair value of foreign exchange derivatives related to cash flow hedges were recognized in equity in fiscal year 2016. Gains of € 11,075,000 (previous year: € 19,817,000) and losses of € 19,870,000 (previous year: € 34,428,000) recognized in equity were transferred to other operating income/other operating losses for the fiscal year. The earnings from currency hedging on plant construction projects –€ 1,053,000 (previous year: –€ 8,730,000) were eliminated from currency earnings. As of the reporting date, the hedging measures had no ineffective portions. B. Braun expects gains of € 2,959,000 and losses of € 12,493,000 recognized in equity to be transferred to the statement of income within the next 12 months. The earnings from the hedges from internal commercial lending is shown in net interest income.

33 Related party transactions

Related party transactions are presented for persons or entities not already included as consolidated companies in the consolidated financial statements. A person or a close member of that person's family is related to a reporting entity if that person has control or joint control over the reporting entity, has significant influence over the reporting entity, or is a member of key management personnel of the reporting entity. An entity is related to a reporting entity if the entity and the reporting entity are members of the same group or one entity is an associate or joint venture of the other entity.

The B. Braun Group purchases materials, inventories, and services from numerous suppliers around the world in the ordinary course of its business. These suppliers include a small number of companies in which the Group holds a controlling interest and companies that have ties to members of B. Braun Melsungen AG's Supervisory Board. Business transactions with such companies are conducted on normal

market terms. From the perspective of the B. Braun Group, these are not materially significant. The B. Braun Group did not participate in any transactions significant for it or for related entities that were in any way irregular, and does not intend to do so in the future.

The following transactions were completed with related persons and entities:

	2016 € '000	2015 € '000
Sale of goods and services		
Related entities	21,784	15,771
of which B. Braun Holding GmbH & Co. KG	(12,826)	(13,732)
of which holdings	(8,958)	(2,039)
Goods and services purchased		
Related entities	57,430	86,356
of which B. Braun Holding GmbH & Co. KG	(21,981)	(22,178)
of which joint ventures	(22,064)	(21,488)
of which holdings	(13,385)	(42,690)

Outstanding items from the acquisition/sale of goods and services and from loans at the end of the fiscal year:

	Dec. 31, 2016 € '000	Dec. 31, 2015 € '000
Outstanding items from the sale of goods and services		
Related entities	1,666	4,120
of which B. Braun Holding GmbH & Co. KG	(529)	(3,577)
of which joint ventures	(384)	(408)
of which holdings	(753)	(135)
Procurement obligations	156	216
Outstanding items from goods and services purchased and from loans		
Related entities	40,680	32,639
of which B. Braun Holding GmbH & Co. KG	(27,095)	(27,064)
of which joint ventures	(1,875)	(1,740)
of which holdings	(11,710)	(3,835)
Key management personnel	75,639	66,099
	116,319	98,738
Procurement obligations	1,605	1,951

Key management personnel are members of the Management Board and members of the Supervisory Board of B. Braun Melsungen AG. In addition to B. Braun Holding GmbH & Co. KG, the affiliated Group includes joint ventures and companies controlled by key management personnel or their close family members. The names of associated companies and joint ventures are listed under Major Shareholdings.

The following items in the statement of financial position contain outstanding balances with related persons and entities:

- Other assets
- Financial liabilities
- Other liabilities

The loans granted by related individuals are short-term. Their interest rates are based on covered bond (Pfandbrief) yields.

Please see Note 27 for details of leasing liabilities to related entities.

Remuneration for members of the Management Board consists of a fixed and a variable, performance-related component. They also receive pension commitments and benefits in kind. Benefits in kind consist mainly of the value assigned for the use of company cars under German tax laws.

In addition to the duties and performance of Management Board members, the criteria for remuneration include the Group's financial position, results, and future projections.

The total remuneration of Management Board members consists of the following:

	2016 € '000	2015 € '000
Fixed remuneration	4,000	3,956
Variable remuneration	6,172	5,079
Pension expense	1,030	1,030
Bonuses	468	273
Other	437	438
	12,107	10,776

Of the total, € 636,000 was attributable to the Chairman of the Management Board as fixed remuneration and € 909,000 as variable remuneration from profit-sharing.

Pension obligations totaling € 25,564,000 exist to active board members. Profit-sharing bonus obligations to board members reported under liabilities to employees, management and shareholders total € 5,995,000. A total of € 28,207,000 has been allocated for pension obligations to former board members and their surviving dependents; current pension payments total € 2,064,000. Supervisory Board remuneration totaled € 698,000.

The remuneration of Supervisory Board members is governed by the articles of incorporation and is approved at the Annual Shareholders' Meeting. The remunerations made to employee representatives on the Supervisory Board for work outside their supervisory activities are in line with the market standards.

The Group has not made any loans to current or former members of the Management Board or Supervisory Board. Liabilities stemming from profit participation rights for board members were € 15,530,000 (previous year: € 13,409,000). See Note 27 for detailed information about bonuses.

The members of the Supervisory Board and the Management Board are listed on pages 2 and 163.

NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

The consolidated statement of cash flows details changes in the B. Braun Group's cash and cash equivalents during the course of the fiscal year. In accordance with IAS 7, cash flows are categorized as those from operating, investing and financing activities. Cash flow from operating activities is calculated using the indirect method.

34 Gross cash flow from operating activities

The gross cash flow of € 753.2 million is the cash surplus from operating activities before any changes in working capital, a decrease of € 14.5 million from the previous year. The change is due primarily to the change in non-current provisions and other non-cash income and expenses.

Cash flow from operating activities of € 822.8 million represents changes in current assets, current provisions, and liabilities (excluding financial liabilities).

The increase in liabilities and short-term provisions less the increase in inventories, receivables and other assets have led to a cash inflow of € 69.6 million. Net cash from operating activities is therefore € 135.3 million above the previous year's level.

35 Cash flow from investing activities

For the purchase of property, plant and equipment, intangible assets, financial assets, and business acquisitions, a total of € 803.4 million was spent in 2016. This was offset by proceeds from the sale of property, plant and equipment and the disposal of holdings (€ 7.1 million), as well as dividends and similar revenues received (€ 13.3 million), resulting in a net cash outflow from investing activities of € 783.1 million. Compared to the previous year, this resulted in a € 70.2 million increase in cash outflow.

Investments made during the year were fully covered by cash flow from operating activities. The remaining free cash flow was –€ 39.7 million (previous year: –€ 25.4 million).

Additions to property, plant and equipment and intangible assets under finance leasing do not result in cash outflows and are therefore not included under investing activities. In the reporting year, these additions totaled € 0.4 million (previous year: € 0.5 million).

36 Cash flow from financing activities

In 2016, cash flow from financing activities amounted to € 10.1 million (previous year: –€ 6.3 million cash outflow). The net balance of proceeds from and repayments of loans was € 49.4 million (previous year: € 36.7 million). Dividend payments and capital contributions by non-controlling interests resulted in a total cash outflow of € 39.2 million (previous year: € 41.8 million). The € 16.4 million change in cash inflows as compared with the previous year is primarily due to lower loan repayments.

37 Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits, and other short-term highly liquid financial assets with residual maturities of three months or less that are subject to no more than insignificant fluctuations in value.

As of December 31st, 2016, restrictions on cash availability totaled € 1.766 million (previous year: € 1.386 million). These restrictions are primarily related to security deposits and collateral for tender business.

SUBSEQUENT EVENTS

No facts came to light after completion of the financial year through to the date of preparation of the consolidated financial statements that have a material effect on the earnings, assets and financial position for fiscal year 2016.

INDEPENDENT AUDITORS' REPORT

The complete annual financial statements and management report for publication in the online edition of the German Federal Gazette (Bundesanzeiger) have been supplemented with the following confirmation note:

We have audited the consolidated financial statements prepared by B. Braun Melsungen AG, Melsungen, Germany, comprising the statement of financial position, statement of income (loss), statement of comprehensive income, statement of cash flows, statement of changes in equity, and notes to the consolidated financial statements, together with the Group management report for the fiscal year from January 1 to December 31, 2016. The preparation of the consolidated financial statements and the Group management report in accordance with IFRS as adopted by the EU, and the additional requirements of German commercial law pursuant to Section 315 a (1) of the German Commercial Code (HGB), is the responsibility of the Management Board of the Company. Our responsibility is to express an opinion on the consolidated financial statements and on the Group management report based on our audit.

We conducted our audit of the consolidated financial statements in accordance with Section 317 HGB and the German generally accepted standards for the audit of financial statements promulgated by the Institut der Wirtschaftsprüfer (IDW). These standards require that we plan and perform the audit such that misstatements materially affecting the presentation of the net assets, financial position, and results of operations in the consolidated financial statements in accordance with the applicable financial reporting framework and in the Group management report are detected with reasonable assurance. Knowledge of the business activities and the economic and legal environment of the Group and expectations as to possible misstatements are taken into account in the determination of audit procedures. The effectiveness of the accounting-related internal control system and the evidence supporting the disclosures in the consolidated financial statements and the Group management report are examined primarily on a test basis within the framework of the audit. The audit includes assessing the annual financial statements of those entities included in consolidation, determining the scope of consolidation, the accounting and consolidation principles used, and significant estimates made by the Management Board, as well as evaluating the overall presentation of the consolidated financial statements and the Group management report. We believe that our audit provides a reasonable basis for our opinion.

Our audit has not led to any reservations.

In our opinion, based on the findings of our audit, the consolidated financial statements comply with IFRS as adopted by the EU and the additional requirements of German commercial law pursuant to Section 315 a (1) HGB and provide a true and fair view of the net assets, financial position, and results of operations of the Group in accordance with these requirements. The Group management report is consistent with the consolidated financial statements and, as a whole, provides an appropriate view of the Group's position and appropriately presents the opportunities and risks of future development.

Kassel, Germany, March 8, 2017

PricewaterhouseCoopers GmbH
Wirtschaftsprüfungsgesellschaft

Dr. Peter Bartels
German Public Auditor

Dr. Bernd Roese
German Public Auditor

MAJOR SHAREHOLDINGS

Company name and location	As of December 31, 2016			Employees
	Holding in % ¹	Equity € '000	Sales € '000	
Germany				
Aesculap AG, Tuttlingen ²	100.0	76,084	771,231	3,551
Aesculap International GmbH, Tuttlingen ²	100.0	205,777	0	0
Aesculap Suhl GmbH, Suhl ²	100.0	3,680	14,165	121
Almo-Erzeugnisse E. Busch GmbH, Bad Arolsen	60.0	24,538	68,476	384
B. Braun Avitum AG, Melsungen ²	94.0	87,088	411,604	884
B. Braun Avitum Saxonia GmbH, Radeberg ²	94.0	13,181	92,497	756
B. Braun Facility Services GmbH & Co. KG, Melsungen	100.0	-3,557	19,247	85
B. Braun Nordamerika Verwaltungsgesellschaft mbH, Melsungen ²	100.0	149,309	0	0
B. Braun Surgical GmbH, Melsungen ²	100.0	154,447	0	0
B. Braun TravaCare GmbH, Hallbergmoos ²	100.0	42	40,827	66
B. Braun Vet Care GmbH, Tuttlingen ²	100.0	-148	14,904	19
DTZ Dialyse Trainings-Zentren GmbH, Nuremberg ²	94.0	41,875	30,604	352
Inko Internationale Handelskontor GmbH, Roth ²	100.0	4,563	14,206	25
Nutrichem diät + pharma GmbH, Roth ²	100.0	29,815	47,110	311
TransCare Service GmbH, Neuwied	55.0	3,072	13,379	106
Europe				
Aesculap Chifa Sp. z o.o., Nowy Tomyśl/Poland	98.9	108,906	160,516	2,088
Aesculap SAS, Chaumont/France	100.0	11,638	14,663	118
Avitum S.R.L., Timisoara/Romania	94.0	1,337	23,437	445
B. Braun Adria d.o.o., Zagreb/Croatia	36.0	8,970	13,067	35
B. Braun Austria Ges. m.b.H., Maria Enzersdorf/Austria	60.0	55,460	60,537	145
B. Braun Avitum France SAS, Gradignan/France	94.0	14,755	16,120	19
B. Braun Avitum Hungary Egeszsegügyi Szolgaltato Zrt., Budapest/Hungary	94.0	19,894	29,430	703
B. Braun Avitum Italy S.p.A., Mirandola/Italy	94.0	30,754	62,849	247
B. Braun Avitum Poland Sp.z o.o., Nowy Tomyśl/Poland	95.1	9,184	33,642	424
B. Braun Avitum Russland Clinics OOO, St. Petersburg/Russia	94.0	7,011	23,758	666
B. Braun Avitum Russland OOO, St. Petersburg/Russia	94.0	60,405	48,994	53
B. Braun Avitum s.r.o., Bratislava/Slovakia	93.7	1,177	14,025	215

¹ Effective share

² Entities with profit-and-loss transfer agreement

Company name and location	As of December 31, 2016			Employees
	Holding in % ¹	Equity € '000	Sales € '000	
B. Braun Avitum s.r.o., Prague/Czech Republic	93.7	7,922	27,234	365
B. Braun Avitum Servicios Renales S.A., Rubi/Spain	96.4	9,479	15,519	197
B. Braun Avitum Turkey Sanayi Ticaret Anonim Sirketi, Ankara/Turkey	94.0	7,553	7,282	15
B. Braun Avitum (UK) Ltd., Sheffield/England	94.0	4,336	28,718	249
B. Braun Hospicare Ltd., Co. Sligo/Ireland	100.0	3,663	15,887	115
B. Braun Medical AB, Danderyd/Sweden	100.0	3,583	50,171	53
B. Braun Medical AG, Sempach/Switzerland	51.0	248,347	301,249	951
B. Braun Medical A/S, Frederiksberg/Denmark	100.0	2,436	19,407	33
B. Braun Medical A/S, Vestskogen/Norway	100.0	2,370	22,151	34
B. Braun Medical B.V., Oss/Netherlands	100.0	6,817	61,999	159
B. Braun Medical EOOD, Sofia/Bulgaria	60.0	4,652	14,250	57
B. Braun Medical International S.L., Rubi/Spain	100.0	168,798	5,337	23
B. Braun Medical Kft., Budapest/Hungary	60.0	38,389	80,719	1,128
B. Braun Medical Lda., Barcarena/Portugal	100.0	33,358	53,904	147
B. Braun Medical LLC, St. Petersburg/Russia	100.0	42,849	123,856	440
B. Braun Medical Ltd., Dublin/Ireland	100.0	4,292	26,333	47
B. Braun Medical Ltd., Sheffield/England	100.0	51,666	163,429	534
B. Braun Medical N.V., Diegem/Belgium	100.0	2,887	34,467	75
B. Braun Medical Oy, Helsinki/Finland	100.0	3,704	39,443	52
B. Braun Medical S.A., Rubi/Spain	100.0	247,925	258,071	1,286
B. Braun Medical S.A.S., Boulogne-Billancourt/France	100.0	86,041	310,291	1,283
B. Braun Medical s.r.o., Bratislava/Slovakia	70.0	8,029	27,401	29
B. Braun Medical s.r.o., Prague/Czech Republic	70.0	24,020	64,008	184
B. Braun Medikal Dis Ticaret A.S., Sariyer Istanbul/Turkey	100.0	6,435	14,809	83
B. Braun Milano S.p.A., Milan/Italy	100.0	35,792	123,204	224
B. Braun Sterilog (Birmingham) Ltd., Sheffield/England	100.0	-5,088	13,849	229
B. Braun Sterilog (Yorkshire) Ltd., Sheffield/England	100.0	-4,259	9,489	166
B. Braun Surgical SA, Rubi/Spain	100.0	129,516	169,399	803
B. Braun VetCare S.A., Rubi/Spain	100.0	7,656	12,691	26
Gematek OOO, St. Petersburg/Russia	100.0	16,417	10,927	245
MCP-Medicare LLC, St. Petersburg/Russia	94.0	6,156	14,732	288
SC B. Braun Medical S.R.L., Remetea Mare/Romania	61.9	5,217	25,911	100
Suturex Et Renodex S.A.S., Sarlat/France	100.0	15,488	16,708	162

¹ Effective share

Company name and location	As of December 31, 2016			Employees
	Holding in % ¹	Equity € '000	Sales € '000	
North America				
Aesculap Inc., Center Valley/USA	95.5	108,209	206,037	473
Aesculap Implant Systems LLC, Center Valley/USA	95.5	- 28,488	49,601	108
B. Braun Interventional Systems Inc., Bethlehem/USA	95.5	38,954	39,605	43
B. Braun Medical Inc., Bethlehem/USA	95.5	458,122	1,088,140	5,203
B. Braun of America Inc., Bethlehem/USA	95.5	93,983	0	0
B. Braun of Canada Ltd., Mississauga/USA	95.5	2,772	19,986	17
Central Admixture Pharmacy Services Inc., Santa Fe Springs/USA	95.5	103,940	193,052	551
Asia-Pacific				
Ahlcon Parenterals (India) Limited., New Delhi/India	96.1	10,305	17,081	810
B. Braun Aesculap Japan Co Ltd., Tokyo/Japan	100.0	53,988	129,621	584
B. Braun Australia Pty. Ltd., Sydney/Australia	100.0	16,768	58,570	109
B. Braun Avitum Philippines Inc., Taguig City/Philippines	100.0	10,051	34,894	226
B. Braun Avitum (Shanghai) Trading Co. Ltd., Shanghai/China	94.0	44,764	124,065	244
B. Braun Korea Co. Ltd., Seoul/South Korea	100.0	14,163	73,934	134
B. Braun Medical (H.K.) Ltd., Hong Kong/China	100.0	76,103	194,202	30
B. Braun Medical (India) Pvt. Ltd., Mumbai/India	100.0	23,400	63,372	960
B. Braun Medical Industries Sdn. Bhd., Petaling Jaya/Malaysia	100.0	465,233	453,194	7,361
B. Braun Medical (Shanghai) International Trading Co. Ltd., Shanghai/China	100.0	16,204	203,885	977
B. Braun Medical Supplies Inc., Taguig City/Philippines	100.0	11,342	27,287	169
B. Braun Medical Supplies Sdn. Bhd., Petaling Jaya/Malaysia	100.0	30,824	51,745	165
B. Braun Medical (Suzhou) Company Limited, Suzhou/China	100.0	15,473	51,672	426
B. Braun Pakistan (Private) Ltd., Karachi/Pakistan	100.0	941	21,880	121
B. Braun Singapore Pte. Ltd., Singapore	100.0	61,317	25,460	48
B. Braun Taiwan Co. Ltd., Taipei/Taiwan	100.0	5,983	19,839	46
B. Braun (Thailand) Ltd., Bangkok/Thailand	100.0	10,405	30,892	132
B. Braun Vietnam Co. Ltd., Hanoi/Vietnam	100.0	59,950	75,115	1,071
PT. B. Braun Medical Indonesia, Jakarta/Indonesia	99.0	60,390	82,562	526
Latin America				
B. Braun Aesculap de México S.A. de C.V., Mun. Santa Cruz Atizapán/Mexico	100.0	11,011	29,308	242
B. Braun Medical de México S.A.PI. DE C.V., Mun. Santa Cruz Atizapán/Mexico	51.0	1,496	11,094	54
B. Braun Medical Peru S.A., Lima/Peru	100.0	19,259	27,711	435
B. Braun Medical S.A., Bogotá/Columbia	100.0	9,055	32,335	239
B. Braun Medical S.A., Buenos Aires/Argentina	100.0	15,780	48,403	374
B. Braun Medical S.A., Quito/Ecuador	100.0	16,455	24,127	112
B. Braun Medical SpA, Santiago de Chile/Chile	86.1	7,231	40,502	154
Laboratorios B. Braun S.A., São Gonçalo/Brazil	100.0	150,041	147,410	1,486

¹ Effective share

Company name and location	As of December 31, 2016			Employees
	Holding in % ¹	Equity € '000	Sales € '000	
Africa and the Middle East				
B. Braun Avitum (Pty) Ltd., Johannesburg/South Africa	100.0	1,948	10,433	314
B. Braun Medical (Pty) Ltd., Johannesburg/South Africa	100.0	7,564	40,685	243
E. Owen and Partners, Johannesburg/South Africa	100.0	278	16,761	14
Other shareholdings				
Babolat VS, Lyon/France ³⁾	28.0	69,084	123,716	236
Medical Service und Logistik GmbH, Recklinghausen ³⁾	50.0	565	41,130	8
Rhön-Klinikum AG, Bad Neustadt an der Saale ^{3) 4)}	21.6	1,137,218	885,304	16,377
Schöllly Fiberoptic GmbH, Denzlingen ³⁾	28.0	48,233	103,856	328

¹ Effective share

³ Consolidated at equity

⁴ Values taken from published Q3 interim report

Values correspond to financial statements prepared in accordance with IAS/IFRS. Amounts for foreign entities are converted using the mid-rate on December 31 for equity and the average annual rate for sales.

REPORT OF THE SUPERVISORY BOARD

The Supervisory Board of B. Braun Melsungen AG has performed its statutory duties and obligations in accordance with the applicable laws, articles of incorporation, and bylaws, and to advise and monitor management.

In three ordinary sessions, the Management Board reported to the Supervisory Board on the recent performance of the company, its financial status, and major investment projects.

Specific topics of the Supervisory Board's deliberations were reports on the implementation of the 2020 strategy in the USA, the current situation in Brazil, and ongoing major investment projects. Furthermore, the quality report, the importance of new production methods, and the development of digitalization in the B. Braun Group were presented. In its session on November 29, 2016, the Supervisory Board proposed modifying the terms of profit participation rights for passing a resolution to the general assembly. In addition, the Supervisory Board received the 2015 personnel report. The Supervisory Board discussed and adopted the 2016 earnings expectations, and also deliberated on transactions which require its approval in accordance with the articles of incorporation.

In addition, the Chairman of the Supervisory Board routinely exchanged information and thoughts with the Chairman of the Management Board with regard to major developments in the business performance of the company and the Group, as well as upcoming decisions.

This year as well, the Supervisory Board performed an efficiency audit on a voluntary basis. This self-evaluation by the Supervisory Board revealed that the Supervisory Board is efficiently organized and that the Management and Supervisory Boards work very well together.

The subjects of the two consultations of the audit committee were, in particular, the individual and

consolidated 2016 financial statements of B. Braun Melsungen AG, prepared by the Management Board, the current course of business development, explanations for the development of other intangible assets from the area of research and development, the annual report from internal auditing on performed audits, and the auditing plan and priorities. In addition, the audit committee received the compliance report of B. Braun Melsungen AG and the Management Board's risk report. Other topics included a report on current issues in international taxation and on the effects of the statutory auditor reform law for B. Braun Melsungen AG, as well as status reports on the current situations in Brazil and Columbia and selected investment projects. Planning for the year-end audit was also presented. The audit committee reported on these topics during the Supervisory Board sessions and put forward its recommendations.

The personnel committee of the Supervisory Board met three times in 2016. At its meeting on March 22, 2016, it proposed to the Supervisory Board the allocation of profit participation rights according to the B. Braun Incentive Scheme to the members of the Management Board, a resolution on the annual objectives of individual board members, and the determination of the annual fixed salary of a board member. The Supervisory Board approved the allocation and the resolutions in its session on the same date. In its meeting on July 7, 2016, the personnel committee recommended to the Supervisory Board that Prof. Dr. Hanns-Peter Knaebel be re-appointed as a full member of the Management Board until March 31, 2022. The Supervisory Board formulated the resolution accordingly in its subsequent session and confirmed the appointment. Discussions regarding general human resources topics in particular were another component of the 2016 human resources committee sessions.

Mr. Otto Philipp Braun has resigned as member of the Management Board on best and mutual terms,



→ Front row from left:

Kathrin Dahnke

Member of the Management Board of Wilh. Wehrhahn KG, Neuss

Alexandra Friedrich*

Vice Chairman of the Workers' Council of B. Braun Melsungen AG, Melsungen

Edeltraud Glänzer*

Member of the Managing Board of IG BCE, Hanover

Ekkehard Rist*

Vice Chairman of the Workers' Council of B. Braun Germany, Chairman of the Workers' Council of Aesculap AG, Tuttlingen

Prof. Dr. h. c. Ludwig Georg Braun

Chairman, Former Chairman of the Management Board of B. Braun Melsungen AG, Melsungen

Michael Guggemos*

Management Spokesman of the Hans Böckler Foundation, Dusseldorf

→ Second row from left:

Barbara Braun-Lüdicke

Businesswoman, Melsungen

Rainer Hepke*

Chairman of the Workers' Council of B. Braun Melsungen, Melsungen

Prof. Dr. Dr. h. c. Markus W. Büchler

Medical Director, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital

→ Third row from left:

Manfred Herres*

Production Director, B. Braun Avitum, B. Braun Melsungen AG, Melsungen

Prof. Dr. Oliver Schnell

Managing Director of Sciarc GmbH, Baierbrunn

Peter Hohmann*

Vice Chairman, Chairman of the Workers' Council of B. Braun Germany, Chairman of the Workers' Council of B. Braun Melsungen AG, Melsungen

Dr. Joachim Rauhut

Chief Financial Officer of Wacker Chemie AG, Munich

→ Back row from left:

Mike Schwarz*

Member of the Workers' Council of B. Braun Melsungen AG, Melsungen

Hans-Carsten Hansen

President Human Resources of BASF SE, Ludwigshafen

Prof. Dr. Thomas Rödder

Tax Advisor and Certified Public Accountant, Partner, Flick Gocke Schaumburg, Bonn

*Chosen by the employees

effective February 21, 2017. This was confirmed by the Supervisory Board on the same day by circular resolution. The Supervisory Board expresses its thankful appreciation to Mr. Braun for his nine years of service to the B. Braun organization.

B. Braun Melsungen AG's financial statements and management report for the fiscal year 2016, prepared by the Management Board, the Group's consolidated financial statements, and the consolidated management report were audited by the PricewaterhouseCoopers AG accounting firm, Kassel, Germany, which was appointed the auditor of annual accounts at the annual meeting on March 22, 2016. The auditor raised no objections and issued an unqualified audit opinion.

The term of office of the Supervisory Board ended at the end of the general assembly on March 22, 2016. Dr. h. c. August Oetker left the Supervisory Board at this time.

The general assembly elected Ms. Kathrin Dahnke, member of the Management Board of Wilh. Werhahn KG, Neuss, as a new Supervisory Board member to replace Dr. August Oetker. As additional representatives of the shareholders, Prof. Dr. h. c. Ludwig Georg Braun, Ms. Barbara Braun-Lüdicke, Prof. Dr. Dr. h. c. mult. Markus Büchler, Mr. Hans-Carsten Hansen, Dr. Joachim Rauhut, Prof. Dr. Thomas Rödder, and Prof. Dr. Oliver Schnell were re-elected to the Supervisory Board.

Ms. Alexandra Friedrich, Ms. Edeltraud Glänzer, Mr. Michael Guggemos, Mr. Rainer Hepke, Mr. Manfred Herres, Mr. Peter Hohmann, Mr. Ekkehard Rist, and Mr. Mike Schwarz were elected to the Supervisory Board as employee representatives.

Following the general assembly, the Supervisory Board elected Prof. Dr. h. c. Ludwig Georg Braun as Chairman and Mr. Peter Hohmann as Vice Chairman in its constituent assembly.

The statutory auditor participated in the discussions of the Supervisory Board and the audit committee regarding the financial statements and the consolidated financial statements, and reported on the main findings of its audit. The Supervisory Board's

review of the financial statements, the management report, and the proposal for appropriation of the net profit of B. Braun Melsungen AG, as well as the consolidated financial statements and the Group management report, led to no objections in correspondence with the results of independent auditors' report. We have therefore approved the financial statements compiled by the Management Board, which are thereby recorded in accordance with § 172 AktG.

The Supervisory Board concurs with the proposal of the Management Board to appropriate the consolidated net income.

The Management Board created a report on the relationships with associated companies for the 2016 fiscal year, in accordance with § 312 AktG. The Supervisory Board has reviewed this report; no objections have been raised. The independent auditor has reviewed the report and issued the following audit certificate:

"On completion of our audit in accordance with professional standards, we confirm that

1. the factual statements made in the report are correct,
2. the company's compensation with respect to the transactions listed in the report was not inappropriately high."

The Supervisory Board is in agreement with the results of the independent auditor's report. In accordance with the final results of the Supervisory Board's review, no objections are to be raised to the final declaration by the Management Board which is included in the report.

The Supervisory Board would like to thank the Management Board for its excellent and successful collaboration, and all employees of the B. Braun Group for the contributions they made in the reporting period.

Melsungen, March 2017
The Supervisory Board

GLOSSARY

A

Angioplasty

Expansion of a restricted blood vessel by a catheter inserted into the vascular system.

Apheresis

Blood purification method for removing individual components (fats, antibodies or toxins) from the blood.

Arthroscopy

A minimally invasive procedure in which joints are treated through a small surgical incision using an endoscope for diagnosis and treatment.

Asset-backed securities (ABS)

Bonds or notes secured by accounts receivable.

B

Biologization

Amalgamation of technical and biological components within a device or a medical process.

Bipolar instruments

Instruments which enable physicians to safely control bleeding with minimal risk to the patient using high-frequency electricity.

C

Cardio-thoracic surgery

Organ surgery in the region of the chest.

Cash flow hedges

Financial instruments that are used to secure cash flows against the risk of possible fluctuations that can influence the period result.

Cash pooling

A cash management technique that allows the internal balancing of liquidity within the Group.

Centers of Excellence (CoE)

Centers within the global B. Braun organization, incorporating research, development, manufacturing and marketing for specific product groups.

CETA

Acronym for Trade Agreement between Canada and the European Union (Comprehensive Economic and Trade Agreement).

CIW

Key performance indicator. Acronym for Coverage in Weeks. This KPI refers to the delivery capacity in weeks covered by the current inventory on hand.

Code of conduct

This sets the rules for the company's global operations and defines ethically proper conduct for all employees in terms of the global B. Braun compliance management system.

Compliance

Adherence to rules, laws and the company's voluntary codes of conduct.

Corporate governance

The organizational framework for management and supervision of the company which is largely defined by lawmakers and the company's owners.

Cytostatics

Toxic substances for treating tumor diseases.

D

Derivative financial instruments

Forward transactions for securing interest and currency positions against risks that result from market interest and exchange rate fluctuations.

Dialysis

A blood cleansing process used in the treatment of kidney failure.

DPO

A key performance indicator; short for Days Payables Outstanding. Describes the period of time between the date the invoice is received and the date payment is made.

DSO

A key performance indicator; short for Days Sales Outstanding. Describes the period of time between the invoicing date and the date payment is received.

Dual sourcing

An element of procurement strategy in which the same goods are purchased from different suppliers in order to minimize the risk of supply interruptions.

E

EBIT

A key performance indicator; short for Earnings before Interest and Taxes.

EBITDA

A key performance indicator; short for Earnings before Interest, Taxes, Depreciation and Amortization.

EBITDA margin

Key performance indicator. EBITDA as a percentage of sales.

EMAS

Acronym for Eco Management and Audit Scheme, also known as the eco audit. EMAS was developed by the European Union and consists of environmental management and an environmental audit for organizations that want to improve their environmental performance.

EN ISO 9001

An international standard that establishes globally recognized requirements for quality management systems.

EN ISO 9626:2016

An international standard that specifies global requirements and testing procedures for tubes that are manufactured in the form of cannulae for use as components in medical products.

EN ISO 14001

An international environmental management standard that establishes globally recognized requirements for environmental management systems.

Endoprosthesis

An implant that is placed inside the body to permanently replace a missing body part.

Endoscopy

A method for observing body cavities and hollow organs using small, tube-shaped optical devices.

Equity method

Accounting method for recognition of long-term investments in the financial statements of a company that has significant control over another company. The carrying amount – as based on the acquisition costs of the investment – is subsequently adjusted to account for the investor's share in the company's income or loss.

F**FDA**

Acronym for Food & Drug Administration, a US government agency.

Fiscal policy

Instruments employed by the government to manage fluctuations in the economy by means of taxes and government spending.

Force majeure

Synonym for "act of god." Force majeure exists if damage occurs which is not in the nature of the object in question and the event could not have been prevented through the exercise of reasonable care.

G**GDP**

Acronym for Gross Domestic Product.

Goodwill

This represents an intangible asset resulting from the purchase of another company or the purchase of shares in another company.

H**Hemodialysis**

A special blood cleansing process that utilizes the principle of osmosis, i. e. the equalization of concentrations of small-molecule substances in two liquids separated by a semi-permeable membrane.

I**IAS**

Abbreviation for International Accounting Standards for businesses, issued by the International Accounting Standards Board (IASB).

IEC/TR 62653

Guideline for safe operation of medical equipment used for hemodialysis treatment.

IFRS

Abbreviation for International Financial Reporting Standards. International financial reporting guidelines published by the International Accounting Standards Board (IASB).

IMF

Acronym for International Monetary Fund. The IMF is a United Nations organization based in Washington, D.C. in the USA.

Interventional medicine

Form of therapy that requires an acute, urgent intervention into the progression of a disease.

L**Laparoscopy**

An operation performed in the abdomen or pelvis through small incisions with the aid of special endoscopes.

M**Medical Device Excise Tax**

A special tax on medical devices which has been in effect in the US since 2013. In December 2015, this tax was suspended for the years 2016 and 2017.

Minimally invasive surgery

A surgical method designed to minimize injury to the skin and soft tissue.

Monetary policy

Measures taken by the central bank to manage fluctuations in the economy, such as raising or lowering interest rates.

Monofilament suture material

Suture material consisting of only one thread, enabling easier passage through tissue.

Morbidity

Frequency of complications and secondary diseases.

N**Net financial liabilities**

The portion of interest-bearing borrowed capital that is still owed after deducting all available liquid funds. The B. Braun Group calculates net financial liabilities as follows: Financial liabilities minus liquid funds and securities.

Neuromodulation

Therapeutic method for treating severe chronic pain and circulatory disorders.

O**OHSAS 18001**

Abbreviation for Occupational Health and Safety Assessment Series. OHSAS 18001 is a standard that establishes globally recognized requirements for occupational health and safety management systems.

P

Parenteral nutrition

Supplying nutrients intravenously by bypassing the gastrointestinal tract.

Patient Protection and Affordable Care Act (ACA)

A federal law adopted by the US government in 2010 to regulate access to health insurance.

Payer swap

Also known as an interest rate swap (IRS). An instrument in which a party agrees to pay a fixed interest rate and receive a floating rate.

Pen needle

A needle for subcutaneous (under the skin) injection of medications in predefined quantities using an injection pen or device.

Peripheral nerve blockage

Blockage of the nerves that emerge from the brain and the spinal cord and are connected to muscles or the skin in order to transfer information (e.g. pain) to the brain.

R

Regenerative medicine

Scientific field of medicine that deals with therapy for various illnesses, with the primary goal of reestablishing and repairing damaged or entirely destroyed biological material, such as cells, tissue, bone, or organs.

Regional anesthesia

Umbrella term for the administration of anesthesia with the object of eliminating pain in a certain region of the body without rendering the patient unconscious.

S

Second Sourcing

Purchasing strategy in which two manufacturers or suppliers are qualified for delivery of the same product or goods.

Stenosis

Restriction of blood vessels or other hollow organs.

Stent

A small mesh tube (scaffold) that is used to hold open an artery.

Stoma

Surgically created connection between a hollow organ and the skin and having an opening to the outside. A stoma is permanently or temporarily placed.

T

Telemedicine

Diverse medical care concepts in which medical health care services in the fields of diagnostics, therapy, rehabilitation, and medical decision consulting are provided over geographical distances (or offset time). Information and communication technology are used for this.

TTIP

Acronym for Transatlantic Trade and Investment Partnership, a free trade and investment treaty currently being negotiated between the EU and the US.

V

VCI

Acronym for Verband der Chemischen Industrie (German Chemical Industry Association).

Visceral surgery

The surgical treatment of abdominal organs.

W

Working capital

Key performance indicator. Inventories plus current trade accounts receivable less current trade accounts payable.

IMPRINT

B. BRAUN MELSUNGEN AG

Werkanlage PfiEFFewiesen
Europagebäude
34212 Melsungen
Germany
Tel. +49 (0 56 61) 71-0
www.bbraun.com

FOR FURTHER INFORMATION CONTACT

Dr. Bernadette Tillmanns-Estorf
Senior Vice President
Corporate Communications
and Corporate Human Resources
Werkanlage PfiEFFewiesen
Europagebäude
34212 Melsungen
Germany
Tel. +49 (0 56 61) 71-16 30
Email: press@bbraun.com

DISCLAIMER

The annual report is published in German and English. In the event of a discrepancy, the German version takes precedent.

Discover B. Braun's annual report on your PC, tablet or smart phone and view videos and informational graphics at:



www.bbraun.com/xiaoqian






SALES
6,471.0
EUR MILLION

CONSOLIDATED
NET INCOME
396.0
EUR MILLION



RESEARCH
EXPENSES
291.4
EUR MILLION

SALES
BY DIVISION



B. Braun
Hospital Care
2,991
EUR million

B. Braun Aesculap
1,725
EUR million

B. Braun OPM
782
EUR million

B. Braun Avitum
945
EUR million

EBITDA
975.0
EUR MILLION

58,037
EMPLOYEES



232
CORPORATE
SOCIAL
RESPONSIBILITY
PROJECTS



INVESTMENTS
806.7
EUR MILLION

SALES
BY REGION



Germany
1,097
EUR million

Europe
without Germany
2,071
EUR million

North America
1,536
EUR million

Asia-Pacific
1,163
EUR million

Latin America
400
EUR million

Africa and
the Middle East
204
EUR million

Through its subsidiaries and holdings,
B. Braun operates in

64 countries.

